

PRV

PATENT- OCH REGISTRERINGSVERKET  
PatentavdelningenIntyg  
Certificate

REC'D 01 MAR 2005

WIPO PCT

Härmed intygas att bifogade kopior överensstämmer med de  
handlingar som ursprungligen ingivits till Patent- och  
registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of  
the documents as originally filed with the Patent- and  
Registration Office in connection with the following  
patent application.


(71) Sökande Lars Pettersson, Södra Sandby SE  
Applicant (s)

(21) Patentansökningsnummer 0400346-3  
Patent application number

(86) Ingivningsdatum 2004-02-13  
Date of filing

Stockholm, 2005-02-18

För Patent- och registreringsverket  
For the Patent- and Registration Office

  
Görel Gustafsson  
Avgift  
Fee

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

AWAPATENT AB

Kontor/Handläggare  
Malmö/Kristina Walls/KRA

ACTIVE BIOTECH AB

Ansökningsnr

Vår referens  
SE-21006827

1

STEROIDS FOR CANCER TREATMENTField of the invention

The present invention relates to novel compounds which are  $7\alpha$ -substituted 17-alkylene-16 $\alpha$ -hydroxy steroid-5-ol estrogens. This invention specifically relates to 5 estrogen derivatives where the  $7\alpha$ -substituent is chosen in such a way that it conveys anti-estrogenic properties to the compound. The present invention also relates to use of said compounds as a medicament, and for the treatment of estrogen dependent disorders, a pharmaceutical 10 composition comprising one or more of said compounds and a method of treatment.

Background and prior art

Estrogens are small molecule ligands that bind to the ligand-binding domain (LBD) of the estrogen receptors 15 ER- $\alpha$  and ER- $\beta$ . The ligand-receptor complex regulates the transcription of certain genes by binding to response elements in the promotor regions of the genes. The receptor protein activates the transcription machinery by a complex mechanism, through the activating functions AF-1 and AF-2 in the ER. For a comprehensive review on (anti)- 20 estrogens, their receptors, structure and function, see ref 1.

There are broadly speaking three types of ligands, 25 all binding to the LBD but showing different pharmacological profiles: the full agonists, e.g. estradiol, which activate through both the AF-1 and the AF-2 activating functions of the receptor; the mixed agonists/antagonists or the so called SERMs (selective ER modulators), e.g. raloxifene, which activate only through the AF-1 and behave either as agonists or as antagonists depending on 30 the cellular context and tissue; the full antagonists, e.g. ICI 182,780, which inhibit both the AF-1 and the AF-2 activating functions.

The full antagonists, the so called pure anti-estrogens, were first described by Bowler et al. (ref 2) and are especially useful for the treatment of breast cancer.

5 The molecular mechanisms at the level of ligand-receptor complex differentiating the full agonist, the SERM, and the full antagonist have recently been elucidated by X-ray crystallography (ref 3,4).

10 In addition to 17 $\beta$ -hydroxy substitution, full antagonist steroidal estrogens typically bear an 11 $\beta$ - or a 7 $\alpha$ -long-chain substituent, which is necessary for the antagonistic property (ref 1). It has been speculated that the 11 $\beta$ - and 7 $\alpha$ -substituents, both for antagonists and agonists, may bind to a common pocket in the receptor 15 protein (ref 5).

20 Recently it was shown that the full antagonist ICI 164,384 binds to the LBD of ER $\beta$  in a 180° flipped orientation around the O3-O17 axis, compared with the estradiol-ER complex (ref 4). In this orientation the 7 $\alpha$ -substituent of ICI 164,384 can occupy the so-called 11 $\beta$ -pocket of the receptor LBD.

25 In order to show potent agonistic effects steroidal estrogens should have a 17-hydroxy group, preferably a 17 $\beta$ -hydroxy, or a 17-keto group. The 17 $\beta$ -hydroxy group in such compounds is often combined with e.g. 17 $\alpha$ -alkyl (or -alkynyl) or 16 $\alpha$ -halide substituents. This type of D-ring 30 substitution pattern has also been used in the 11 $\beta$ - or 7 $\alpha$ -substituted steroidal anti-estrogens reported in the literature, including the 7 $\alpha$ -substituted steroidal compounds of the closest prior-art.

35 In EP0138504 7 $\alpha$ -substituted steroidal compounds, which are 17 $\beta$ -hydroxy substituted, optionally derivatized, or 17-keto substituted, are reported. This document includes the compound ICI 182,780 (3,17 $\beta$ -dihydroxy -7 $\alpha$ -(9-[[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene)).

EP0280618 describes  $7\alpha$ -aryl substituted steroids, including anti-estrogens, which all are  $17\beta$ -hydroxy,  $17\beta$ -acyloxy, or  $17\beta$ -alkoxy substituted compounds.

EP0367576 discloses compounds for use in the inhibition of sex steroid activity. Among these compounds are  $7\alpha$ -substituted estratrienes, preferably substituted with a  $17$ -hydroxy or a  $17$ -keto group.

WO9920646  $7\alpha$ -thioethers are reported as steroidal estrogens and anti-estrogens. The compounds are  $17$ -hydroxy,  $17$ -acyloxy,  $17$ -alkoxy, or  $17$ -keto substituted in the D-ring. The  $17\beta$ -derivatives are preferred.

WO0142186 compounds having hydroxycarbonyl-halo-  
genoalkyl side chains are reported. Some of these compounds are described as  $7\alpha$ -substituted steroidal anti-estrogens, all of which have the  $17\beta$ -hydroxy substitution pattern.

EP0410554  $7\alpha$ -substituted  $14,17\alpha$ -ethano- and -ethenoestratrienes are reported as anti-estrogenic compounds. The compounds are all  $17\beta$ -hydroxy derivatives.

EP0906332 (DE 19622457) reports on  $7\alpha$ - (5-methyl-aminopentyl) -estratrienes and WO9933855 reports on  $11\beta$ -halogen- $7\alpha$ -substituted estrogens. All compounds are  $17\beta$ -hydroxy or  $17\beta$ -acyloxy derivatives.

WO9807740  $7\alpha$ -aminoalkyl-estratrienes are described, all compounds being  $17$ -hydroxy or -acyloxy derivatives. The vast majority of cited compounds are  $17\beta$ -hydroxy derivatives.

#### Summary of the invention

The objective problem of the present invention is to develop novel  $7\alpha$ -substituted steroidal anti-estrogen compounds with a new D-ring substitution pattern, that does not include the above mentioned substitution pattern known for potent estrogens, but still with a retained or higher affinity for the estrogen receptor in comparison with the above disclosed compounds of the prior art.

This kind of novel compounds, in the form of new high affinity steroidal anti-estrogens according to for-

mula I, have been developed by introducing a 17-alkylene-16 $\alpha$ -hydroxyl substitution in the D-ring in combination with 7 $\alpha$ -side-chains to convey antagonistic properties to the steroidal estrogens. The 7-unsubstituted 17-alkylene-5 16- $\alpha$ -hydroxyl derivatives have earlier been described in document WO9708188 as steroidal estrogens with low "sex hormonal" activities, indicating a low binding affinity and/or low estrogenic agonistic potency of these compounds.

10 The inventor of the present invention have unexpectedly found that the compounds of the present invention show equal or even higher affinity to the ER $\alpha$ -receptor, compared with prior art compounds. The 17-alkylene-16 $\alpha$ -hydroxyl substitution pattern can conceptually be combined with any type of anti-estrogenic 7 $\alpha$ -side-chain. Compounds of the present invention that show pure anti-estrogenic activity are especially useful for the treatment of estrogen dependent breast cancer and other estrogen related disorders such as

20 anovulatory infertility  
menstrual disorders  
male pattern baldness  
dysfunctional uterine bleeding

25 endometrial polyps  
benign breast disease  
uterine leiomyomas  
adenomyosis  
ovarian cancer

30 endometrial cancer  
melanoma  
prostate cancer  
cancers of the colon  
CNS cancers

35 endometriosis  
polycystic ovary syndrome  
infertility

and can also be used for contraception in males.


The phrases "antagonistic properties" and "anti-estrogenic properties" used in the present application relates to compounds that antagonise the action of an estrogen at the receptor level.

Detailed description of the invention

The object of the present invention is to provide novel compounds which are 7 $\alpha$ -substituted 17-alkylene-16 $\alpha$ -hydroxy steroidal estrogens.

In a first aspect the present invention relates to a compound of the general formula I

15



I

20 wherein

A is a 8-22 atoms long substituent, which convey anti-estrogenic properties to the compound and which substituent A is defined by D<sub>1-6</sub>, wherein D is chosen from the group comprising R<sub>4</sub>-C(O)R<sub>4</sub>, R<sub>4</sub>S(O)<sub>0-2</sub>R<sub>4</sub>, N(R<sub>4</sub>)<sub>3</sub>, R<sub>4</sub>OR<sub>4</sub> and R<sub>4</sub>(C<sub>6</sub>H<sub>4</sub>)R<sub>4</sub>

wherein R<sub>4</sub> independently represents a bond, or H, or a halogenated or non-halogenated, saturated or unsaturated, mono-, di-, or trivalent C<sub>1</sub>-C<sub>12</sub> hydrocarbon

B', B'' are H, H or H, O-R<sub>3</sub> or O-R<sub>3</sub>, H or H, F or together represent =O;

R<sub>1</sub> is H, or a potentially metabolically unstable group chosen from the group comprising a straight, branched, or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl;

35 R<sub>2</sub> is H, or a potentially metabolically unstable group chosen from the group comprising C<sub>1</sub>-C<sub>6</sub> acyl or benzoyl;

R3 is H, or C1-C3 alkyl, or a metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl; and

X is methylene or a single bond, or

5 pharmaceutically acceptable salts of the compounds of the general formula I.

In one preferred embodiment of the present invention, A is

$-(CH_2)_{4-6}N((CH_2)_{0-2}H)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

10 or

$-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

or

$-(CH_2)_{8-12}C(O)N((CH_2)_{0-2}H)(CY_2)_{2-6}Y$

wherein Y is chosen from H or F

15 or

$-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3$

or

$-C_6H_4-p-O(CH_2)_{3-6}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

or

20  $-C_6H_4-p-O(CH_2)_2NMe_2;$

R1 is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl;

R2 is hydrogen; and

25 R3 is H, or methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.

In another preferred embodiment A is

$-(CH_2)_{4-6}N(CH_3)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

or

30  $-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

or

$-(CH_2)_{10}C(O)N(CH_3)(CY_2)_{2-6}Y$

wherein Y is chosen from H or F

or


35  $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3;$

B', B'' are H, H or H, O-R3 or O-R3, H or H, F;


R1 is H, or methyl, or acetyl, or sulphamoyl; and

R3 is H, or methyl, or acyl;


In still another preferred embodiment of the present invention A is



5 or



or




10 and


R3 is H.

In yet another embodiment the new compound described above is chosen from the group comprising


11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-15-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,



20 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,




25 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,




30 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,


35




5 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




10 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-  
O-acetate,



15 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-  
O-sulfamate,




20 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-  
O-benzoate,




25 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,


9




5 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-  
fluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,



10 7α-[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-  
3,16α-dihydroxy-17-methylene-estra-1,3,5(10)-triene,




15 3,16α-Dihydroxy-17-methylene-7α-[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,



20 3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,


25




30 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

35


10




5 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




10 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,




15 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,




20 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,



25 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




5 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




10 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

15




20 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

25




25 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,


30




35 10-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,



5 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,




10 2-[9-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,




15 11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

20




25 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl-estra-1,3,5(10)-triene,




30 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl-estra-1,3,5(10)-triene,


35




5 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-  
pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-  
triene 3-O-sulfamate,




3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




20 OH  
 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-  
 estra-1,3,5(10)-triene 3-O-sulfamate,




25 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-  
4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-  
pentyl]-estra-1,3,5(10)-triene,




3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6,6-nonafluoro-n-hexyl)-propylamino]-penty1]-estra-1,3,5(10)-triene,




5 11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,




10 10-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,




15 20 11-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methylamide,




25 6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,




30 35 6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




5 6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-  
3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-  
pentyl]-estra-1,3,5(10)-triene,




6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene.




6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-  
 3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-  
 pentyl]-estra-1,3,5(10)-triene,




25 F  
11-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-  
n-hexyl)-undecanoic acid,




35 10-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-  
n-hexyl)-decanoic acid,




5 3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




10 3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




20 11-(3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,



25 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,




5 11-(17-(1,2-Ethylene)-3,16α-dihydroxy-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,




10 11-(17-(1,2-Ethylene)-3,16α-dihydroxy-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

15 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,




20 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,




25 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,

30




30 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,


35




5 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,




10 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,




20 25 17-(1,2-Ethylene)-7α-[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl) sulfinyl]nonyl]-3,16α-dihydroxy-estra-1,3,5(10)-triene,




30 35 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




5 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




10 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,




20 25 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-acetate,



30 35 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,




5 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




10 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

15




20 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

25




17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,


30




35 11-(17-(1,2-Ethylene)-3,16α-dihydroxy-estra-1,3,5(10)-triene-7α-yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,




5 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,




10 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,




15 20 10-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,




25 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,




30 35 2-[9-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,





5 11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,



11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-  
triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-hepta-  
fluoro)-n-butyl-methyl-amide,




17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,




30 OH  
17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-  
pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-  
triene 3-O-sulfamate,


35




5 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




10 17-(1,2-Ethylene)-7 $\alpha$ -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




20 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,



25 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




5 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,


15




11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-  
20 triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-  
undecanoic acid,




10-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,




11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-  
35 undecanoic acid methylester,




5 11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-  
triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-  
undecanoic acid methylester,




2-[9-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,




11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-  
20 1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-  
amide,




25 11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-  
heptafluoro)-n-butyl-methyl-amide,



17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-  
35 1,3,5(10)-triene,




5 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estr-1,3,5(10)-triene,




10 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estr-1,3,5(10)-triene 3-O-sulfamate,

15




15 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estr-1,3,5(10)-triene,




20

20 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estr-1,3,5(10)-triene,




25

25 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estr-1,3,5(10)-triene,




30


30 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estr-1,3,5(10)-triene 3-O-sulfamate,




5 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




10 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,




25 11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,




30 11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,




5 17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,




10 OH F  
 17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-  
 pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-  
 triene,




17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-  
20 estra-1,3,5(10)-triene,




25 17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-  
(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-  
pentyl]-estra-1,3,5(10)-triene,




11-(17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid.




5 11-(17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,




10 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl-estra-1,3,5(10)-triene,




20 25 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




30 35 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,




5 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,



10 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]nonyl]-estra-1,3,5(10)-triene,



15 , and  
17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene



20 25 In a second aspect the present invention relates to a new compound as described above for use as a medicament.

30 In a third aspect the present invention relates to the use of a new compound as described above for the manufacturing of a medicament for the treatment of an estrogen related disorder or condition that benefits from antiestrogen treatment.

35 In one preferred embodiment the estrogen related disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dys-

functional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, poly-  
5 cystic ovary syndrome, infertility and contraception in males.

In another preferred embodiment the estrogen related disorder is estrogen dependent breast cancer.

In a forth aspect the present invention relates to a  
10 pharmaceutical composition comprising a new compound as described above admixed with one or more pharmaceutically acceptable excipients or carriers.

In one preferred embodiment the excipients are chosen from the group comprising filling agents, lubricants,  
15 flavours, colourings, sweetenings, buffers, acidifying agents, diluents and preservatives.

In another preferred embodiment the pharmaceutical composition is administered orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via  
20 implants, rectally, intranasally, transdermally, or vaginally, preferably orally, transdermally or intranasally.

In a fifth aspect the present invention relates to a method of treatment comprising administration of a pharmaceutically effective amount of a new compound as described above or a pharmaceutical composition as described  
25 above to a subject suffering from an estrogen dependent disorder or condition.

In one embodiment the estrogen dependent disorder or condition to be treated is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis,  
30 ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis,

polycystic ovary syndrome, infertility and contraception in males.

In another preferred embodiment the estrogen dependent disorder is estrogen dependent breast cancer.

5 The compounds of the present invention may be given in doses about 0.1-1000 mg/day, preferably in doses about 1-100 mg/day. The compounds of the present invention may be administered orally, by injections, e.g. intramuscular, intravenous, intraperitoneal, or subcutaneous, via  
10 implants, rectally, intranasally, transdermally, vaginally or by any other route suitable to deliver an therapeutically active amount of the compound.

15 The pharmaceutical composition of the present invention comprises a pharmaceutically effective dose of at least one of the compounds according to the present invention, preferably in admixture with one or more pharmaceutically acceptable excipients, diluents or carriers. The amount administered will vary depending on various factors, e.g. age, sex, weight, which disorder or condition that is treated and the compound used. Both local  
20 and systemic administration is possible.

25 With "pharmaceutically acceptable" is meant that the excipients, diluents or carriers must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

30 The pharmaceutical composition can be prepared according to any of the methods well known by a person skilled in the art of pharmacy. Such methods may include the step of bringing the novel compounds of the present invention in contact with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.

35 One or more suitable unit dosage forms comprising a pharmaceutically effective dose of at least one of the compounds according to the present invention, optionally

formulated for sustained release, can be administered by a variety of routes e. g. orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, or vaginally. Preferably, the novel compounds according to the invention are administrated orally, transdermally or intranasally.

Embodiments of the present invention

The present invention will now be described in more detail by the following examples, which are included in order to disclose some embodiments of the invention, but not in any way to limit the scope of the invention.


In the description of the preparative methods, the manipulation of protecting groups is not included. It is obvious for the person skilled in the art that some functional groups, e.g. hydroxy groups, need to be protected, e.g. as acetals, ethers, or silyl ethers, during the synthetic steps.

The novel steroidal anti-estrogens according to the invention can be prepared from 7 $\alpha$ -substituted estradiol or estrone derivatives by methods described in the literature (Scheme 1, WO9708188).

The 7 $\alpha$ -substituted estradiol or estrone derivatives can be prepared by nucleophilic addition to steroidal 6-en derivatives or by alkylating 6-keto-estra-1,3,5(10)-triene derivatives with electrophilic reagents (ref 6). 6-Keto-derivatives can be prepared by oxidation methods described in the literature, e.g. the 2 step procedure using H<sub>2</sub>O<sub>2</sub> and PCC as oxidizing agents (ref 6).


30

35



Scheme 1

15 Thus, the 7 $\alpha$ -substituted estradiol derivative (I) may be oxidized to the estrone derivative (II) by known methods, e.g. by pyridinium chlorochromate (PCC) or tetrabutylammonium perruthenate/N-methylmorpholine N-oxide (TPAP/NMNO) in inert solvents like  $\text{CH}_2\text{Cl}_2$ . The 20 estrone derivative (II) may be reacted with a Wittig-type reagent, like  $\text{Ph}_3\text{PCH}_2$ , preferably in DMSO or toluene as solvent, to give the exo-methylene derivative (III). Allylic oxidation of (III) by  $\text{SeO}_2$  then stereoselectively 25 gives the 17-methylene-16 $\alpha$ -hydroxy derivative (IV). This can also be prepared from 16 $\alpha$ -hydroxy-17-one derivatives by Wittig-type reactions, e.g. using the Tebbe reagent. Cyclopropanation of (IV) to give the 17-(1',2'-ethylene)-16 $\alpha$ -hydroxy derivative (V) may be accomplished by 30 Simmons-Smith like reagents, e.g. by  $\text{CH}_2\text{I}_2/\text{ZnEt}_2$  in  $\text{CH}_2\text{Cl}_2$ . Alternatively, the manipulation of the D-ring can be done prior to the introduction of the 7 $\alpha$ -side chain (Scheme 2) using the same methods as described above.



Scheme 2

15 The 17-alkylene-16 $\alpha$ -hydroxy derivative (VII) can be  
 20 oxidized to give the 6-keto derivative (VIII), which may  
 be 7 $\alpha$ -alkylated to give (IX), e.g. by reacting the eno-  
 late of (VIII) with alkyl iodides in an inert solvent.  
 25 Further transformations of (IX) into 6 $\alpha$ - or 6 $\beta$ -derivati-  
 30 ves may be accomplished by methods known to a person  
 skilled in the art. Thus (IX) can be subjected to reduc-  
 35 tion methods, e.g. by hydride reagents, to give the 6 $\alpha$ -  
 hydroxy derivative (B' = -OH) or the methylene derivative  
 (B', B'' = H, H). The 6 $\alpha$ -hydroxy derivative (B' = -OH) may  
 be epimerized by Mitsunobu-reactions to give 6 $\beta$ -hydroxy  
 derivatives. The 6 $\alpha$ -hydroxy derivative can also be trans-  
 formed into 6-halo derivatives, e.g. by thionyl chloride  
 or by the DAST reagent, or reduced to the methylene deri-  
 40 vative by, e.g. hydride reagents like Et<sub>3</sub>SiH or Bu<sub>3</sub>SnH  
 under acidic or radical-initiated conditions. The 6-halo  
 derivatives can be reacted with nucleophiles, e.g. hyd-  
 45 ride reagents like LiEt<sub>3</sub>BH to give the methylene deriva-  
 tive or with alcohols to give 6-alkoxy derivatives.  
 In the preparative examples column chromatography  
 50 separations were performed using Merck SiO<sub>2</sub> 60 (0.040-  
 0.063 mm) silica gel. TLC analyses were performed on  
 Merck SiO<sub>2</sub> 60 F254 precoated aluminium sheets and the


spots were visualized by charring with 10% aqueous  $H_2SO_4$ . Microwave-assisted reactions were performed in sealed tubes using a PersonalChemistry Smith Synthesizer. MS spectra were recorded with a ThermoFinnigan LCQ. NMR spectra were recorded with a Bruker ARX 400 (400 MHz) with TMS as internal standard.

Preparation of starting materials (SM)

SM1

11-Iodo-undecanoic acid n-butyl-methyl-amide


a. 11-Bromo-undecanoic acid n-butyl-methyl-amide



n-Butylmethylamine (1.31 g, 15.0 mmol) was added to a solution of 11-bromo-undecanoic acid (2.65g, 10.0 mmol), dimethylaminopyridine (DMAP, 0.10 g, 0.82 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (2.20 g, 11.5 mmol) in  $CH_2Cl_2$  (10 ml). The reaction mixture was stirred for 3 h, concentrated at reduced pressure and purified on column chromatography (heptane-EtOAc, 3:2) to give the title compound (2.75 g, 82%) as an oil.

$^1H$  NMR ( $CDCl_3$ )  $\delta$  0.93, 0.96 (2t,  $J=7.3$  Hz, 3H), 1.38-1.68 (m, 18H), 1.44-1.63 (m, 4H), 1.86 (p,  $J=7.2$ , 2H), 2.29 (m, 2H), 2.91, 2.97 (2s, 3H), 3.26, 3.36 (2t,  $J=7.6$  Hz, 2H) 3.41 (t,  $J=7.0$  Hz, 2H).

b. 11-Iodo-undecanoic acid n-butyl-methyl-amide



30

NaI (11.0 g, 73.4 mmol) was added to solution of 11-bromo-undecanoic acid n-butyl-methyl-amide (15.0 g, 44.9 mmol) in acetone (150 ml) under  $N_2$ . The solution was stirred at 60°C over night to give a slurry. Heptane (300 ml) was added and most of the acetone was evaporated. The slurry was filtered through a short column of silica. The silica was washed with heptane/EtOAc (1:1) and the eluate

was concentrated at reduced pressure to give the title compound (17.0 g, 99%) as an oil.


<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.92, 0.95 (2t, J=7.3 Hz, 3H), 1.25-1.42 (m, 14H), 1.44-1.63 (m, 4H), 1.82 (p, J=7.2, 2H), 2.29 (m, 2H), 2.91, 2.96 (2s, 3H), 3.19 (t, J=7.0 Hz, 2H), 3.25, 3.36 (2t, J=7.6 Hz, 2H).

SM2

1-Iodo-9-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-nonane

a. Thiobenzoic acid S-(4,4,5,5,5-pentafluoro-pentyl)

ester




Diisopropyl azodicarboxylate (DIAD, 3.94 ml, 20.0 mmol) was added to a solution of triphenylphosphine (5.25 g, 20.0 mmol) in THF (120 ml) under N<sub>2</sub> at 0°C. After stirring for 30 min a solution of thiobenzoic acid (2.34 ml, 20.0 mmol) and 4,4,5,5,5-pentafluoro-pentanol (1.78 g, 10.0 mmol) in THF (60 ml) was added. The reaction mixture was stirred 0°C for 1 h and then at room temperature over night. The reaction mixture was concentrated at reduced pressure and was purified on column chromatography (heptane-EtOAc, 20:1) to give the title compound (2.95 g, 99%) as an oil.

R<sub>f</sub> (heptane-EtOAc, 20:1)=0.37

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.96-2.05 (m, 2H), 2.11-2.27 (m, 2H), 3.16 (t, J=7.1 Hz, 2H), 7.47 (t, J=7 Hz, 2H), 7.59 (t, J=7 Hz, 1H), 7.97 (t, J=7 Hz, 2H).

b. 9-(4,4,5,5,5-Pentafluoro-pentylsulfanyl)-1-nonanol




Thiobenzoic acid S-(4,4,5,5,5-pentafluoro-pentyl) ester (8.26 g, 27.7 mmol) was added to a solution of t-BuOK (4.49 g, 40.0 mmol) in MeOH (30 ml). After stirring

for 30 min a solution of 9-bromo-1-nonanol (6.18 g, 27.7 mmol) in MeOH (30 ml) was added. The reaction mixture was stirred over night, concentrated at reduced pressure and partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 3:1) to give the title compound (7.70 g, 83%) as an oil which crystallized on standing.

10  $R_f$  (heptane-EtOAc, 3:1) = 0.24

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.28-1.42 (m, 10H), 1.53-1.62 (m, 4H), 1.89 (m, 2H), 2.18 (m, 2H), 2.51 (t, J=7.4 Hz, 2H), 2.59 (t, J=7.0 Hz, 2H), 3.64 (t, J=6.6 Hz, 2H).

c. Methanesulfonic acid 9-(4,4,5,5,5-pentafluoro-pentyl-sulfanyl)-nonyl ester



20           Methanesulphonic acid anhydride (4.35 g, 25.0 mmol) was added to a solution of 9-(4,4,5,5,5-pentafluoropentylsulfanyl)-1-nonanol (7.70 g, 22.9 mmol) and Et<sub>2</sub>NiPr<sub>2</sub> (4.28 ml, 25.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 ml). The reaction mixture was stirred for 2 h, concentrated at reduced pressure and purified on column chromatography (heptane-EtOAc, 3:1) to give the title compound (9.42 g, 99%) as an oil which crystallized on standing.


25

$R_f$  (heptane-EtOAc, 3:1) = 0.28

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.25-1.45 (m, 10H), 1.53-1.62 (m, 2H).

30 1.75 (m, 2H), 1.88 (m, 2H), 2.17 (m, 2H), 2.51 (t,  $J=7.3$  Hz, 2H), 2.59 (t,  $J=7.1$  Hz, 2H), 3.00 (s, 3H), 4.22 (t,  $J=6.6$  Hz, 2H).

d. 1-Iodo-9-(4,4,5,5,5-pentafluoro-pentylsulfonyl)-nonane



Prepared as described for SM1-b using methanesulfonic acid 9-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-nonyl ester (8.48 g, 20.5 mmol) as starting material to give the title compound (8.93 g, 98%) as an oil.


5  $R_f$  (heptane-EtOAc, 3:1)=0.72

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.25-1.43 (m, 10H), 1.58 (m, 2H), 1.77-1.92 (m, 4H), 2.17 (m, 2H), 2.51 (t,  $J=7.5$  Hz, 2H), 2.59 (t,  $J=7.0$  Hz, 2H), 3.19 (t,  $J=7.0$  Hz, 2H).

SM3

10 1-Methylamino-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane

a. Thioacetic acid S-(4,4,5,5,5-pentafluoro-pentyl) ester




15

Prepared as described for SM2-a using thioacetic acid (18.2 g, 239 mmol) and 4,4,5,5,5-pentafluoro-pentanol (21.3 g, 120 mmol) as starting materials. The crude product was purified by distillation (b.p. 68°C/20 mmHg,

20 19.9 g, 70%).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.89 (m, 2H), 2.10 (m, 2H), 2.35 (s, 3H), 2.95 (t,  $J=7.0$  Hz, 2H).

b. 1-Chloro-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane




25

Prepared as described for SM2-b using thioacetic acid S-(4,4,5,5,5-pentafluoro-pentyl) ester (15.0 g, 63.5 mmol) and 1-chloro-3-iodopropane (19.5 g, 95.3 mmol) as starting materials. The crude product (17.8 g) was used in the next step.

30  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.90 (m, 2H), 2.04 (m, 2H), 2.18 (m, 2H),


35 2.61 (t,  $J=7.0$  Hz, 2H), 2.68 (t,  $J=7.0$  Hz, 2H), 3.66 (t,  $J=6.3$  Hz, 2H).

c. 1-Iodo-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane



Prepared as described for SM1-b using 1-chloro-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane (17.8 g, 65.8 mmol) and NaI (14.8 g, 98.6 mmol) as starting materials to give the title compound (20.0 g, 84%).  
 10  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.90 (m, 2H), 2.07 (m, 2H), 2.18 (m, 2H), 2.61 (t,  $J=7.2$  Hz, 2H), 2.63 (t,  $J=7.0$  Hz, 2H), 3.29 (t,  $J=6.7$  Hz, 2H).

d. 1-Methylamino-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane




1-Iodo-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane (20.0 g, 55.2 mmol) was added to a solution of  $\text{MeNH}_2$  (90 mL, aq. 40%) and  $\text{MeCN}$  (400 mL). The solution was stirred at 90°C over night and was then concentrated at reduced pressure. The residue was partitioned between  $\text{CH}_2\text{Cl}_2$  and  $\text{NaHCO}_3$  (sat.). The aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$ , and the combined organic phases were dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure to give the title compound (13.0 g, 89%) as an oil.  
 20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.77 (m, 2H), 1.89 (m, 2H), 2.17 (m, 2H), 2.44 (s, 3H), 2.58 (t,  $J=7.3$  Hz, 2H), 2.60 (t,  $J=7.1$  Hz, 2H), 2.68 (t,  $J=7.0$  Hz, 2H).  
 25

30  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.77 (m, 2H), 1.89 (m, 2H), 2.17 (m, 2H), 2.44 (s, 3H), 2.58 (t,  $J=7.3$  Hz, 2H), 2.60 (t,  $J=7.1$  Hz, 2H), 2.68 (t,  $J=7.0$  Hz, 2H).

SM4

11-(3,17 $\beta$ -Dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide (ICI 164.384)

a. 3,17 $\beta$ -Di(tetrahydropyranloxy)-estra-1,3,5(10)-triene


5 

10 2,3-Dihydropyran (30 ml, 328 mmol) was added to a solution of 3,17 $\beta$ -dihydroxy-estra-1,3,5(10)-triene (20.0 g, 73.5 mmol) and p-TSA (0.2 g) in CH<sub>2</sub>Cl<sub>2</sub> (200 ml). The reaction mixture was stirred for 3 h at room temperature.

15 EtN(iPr)<sub>2</sub> (0.5 ml) was added and the reaction mixture was concentrated at reduced pressure and purified on column chromatography (heptane-CH<sub>2</sub>Cl<sub>2</sub>, 1:1 then CH<sub>2</sub>Cl<sub>2</sub>) to give the title compound (32.3 g, 100%) as an oil, which crystallized on standing.

18 R<sub>f</sub> (heptane-EtOAc, 1:1)=0.79  
<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.80, 0.82 (2s, 3H), 2.83 (m, 2H), 3.49 (m, 1H), 3.59 (m, 1H), 3.71, 3.72 (2t, J=8 Hz, 1H), 3.92 (m, 2H), 4.65, 4.67 (2m, 1H), 5.38 (broad s, 1H), 6.78 (d, J=2 Hz, 1H), 6.84 (d, J=8,6 Hz, 2 Hz, 1H), 7.18, 7.20 (2d, J=8.6 Hz, 2 Hz, 1H).

20 b. 3,17 $\beta$ -Di(tetrahydropyran-2-yl)-6-keto-estra-1,3,5(10)-triene

25 


30 HN(iPr)<sub>2</sub> (17.3 ml, 123 mmol) was added to a solution of n-BuLi (56.0 ml, 2.2 M in hexanes, 123 mmol) in THF (170 ml) under N<sub>2</sub> at -20°C. The temperature was lowered to -78°C and a solution of t-BuOK (13.8 g, 123 mmol) in THF (125 ml) was added. After stirring for 10 min a solution of 3,17 $\beta$ -di(tetrahydropyran-2-yl)-estra-1,3,5(10)-triene (13.6 g, 30.9 mmol) in THF (70 ml) was added dropwise under 15 min. The reaction mixture was stirred at -78°C for 3 h. B(OMe)<sub>3</sub> (45.0 ml, 396 mmol) was added dropwise and the reaction mixture was then stirred at 0°C for

1.5 h.  $H_2O_2$  (85 ml, aq 30%) was added to give first a turbid reaction mixture then a white precipitated gum (borates, mechanical stirrer or big magnetic stirring bar recommended). After stirring for 1 h at room temperature, 5 the reaction mixture was cooled to 0°C and aq.  $Na_2S_2O_3$  (100 ml, 1.0 M) was added in portions. After stirring for 20 min the reaction mixture was partitioned between EtOAc and water. The organic phase was washed with water and brine, dried ( $Na_2SO_4$ ) and concentrated at reduced pressure 10 to give the 6-hydroxy derivative (14.8 g, quant.,  $R_f$  (heptane-EtOAc, 1:1)=0.58, contained 15-20% starting material by NMR).

The 6-hydroxy derivative (14.7 g) was dissolved in  $CH_2Cl_2$  (150 ml) and pyridinium chlorochromate (PCC, 14.7 g, 68 mmol) was added at 0°C under  $N_2$  in portions for 15 min. The reaction mixture was stirred at 0°C for 15 min, then at room temperature for 1.5 h. Et<sub>2</sub>O (150 ml) was added and after 5 min stirring, the slurry was filtered through silica. The filtrate was concentrated at reduced pressure and purified on column chromatography (heptane-EtOAc, 5:1) to give the title compound (7.50 g, 51 %) as a syrup.

$R_f$  (heptane-EtOAc, 3:1)=0.38

<sup>1</sup>H NMR ( $CDCl_3$ )  $\delta$  0.81, 0.82 (2s, 3H), 2.20 (m, 1H), 2.35 (m, 1H), 2.47 (m, 1H), 2.73 (dd,  $J=16.9, 3.4$  Hz, 1H), 3.50 (m, 1H), 3.60 (m, 1H), 3.72, 3.75 (2t,  $J=8.5$  Hz, 1H), 3.90 (m, 2H), 4.64, 4.68 (2m, 1H), 5.47 (m, 1H), 7.22 (m, 1H), 7.34 (m, 1H), 7.71, 7.72 (2d,  $J=2.7$  Hz, 1H).  
 30 c. 11-(3,17 $\beta$ -Di(tetrahydropyranyloxy)-6-keto-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide




t-BuOK (2.04 g, 18.2 mmol) was added to a solution of 3,17 $\beta$ -di(tetrahydropyranloxy)-6-keto-estra-1,3,5(10)-triene (7.50 g, 16.5 mmol) in dimethoxyethane (75 ml) under N<sub>2</sub>. After 10 min stirring BEt<sub>3</sub> (20.0 ml, 1.0 M in THF, 20.0 mmol) was added and the reaction mixture was stirred for 1 h. A solution of 11-iodo-undecanoic acid n-butyl-methyl-amide (6.48 g, 17.0 mmol) in dimethoxyethane (10 ml) was added. The reaction mixture was stirred for 1 h and then a second batch of t-BuOK (2.04 g, 18.2 mmol) was added. The reaction mixture was stirred over night and was then partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 3:1 then 2:1) to give the title compound (6.87 g, 59%) as an oil.

R<sub>f</sub> (heptane-EtOAc, 2:1)=0.29

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.80, 0.82 (2s, 3H), 0.92, 0.95 (2t, J=7.2 Hz, 3H), 2.28 (m, 2H), 2.35 (m, 1H), 2.44 (m, 1H), 2.70 (m, 1H), 2.90, 2.96 (2s, 3H), 3.25, 3.26 (2t, J=7.5 Hz, 2H), 3.49 (m, 1H), 3.61 (m, 1H), 3.74, 3.77 (2t, J=8.5 Hz, 1H), 3.91 (m, 2H), 4.65, 4.68 (m, 1H), 5.46 (m, 1H), 7.20 (d, J=8.6 Hz, 1H), 7.31, 7.32 (2d, J=8.6, 1H), 7.69 (broad s, 1H).

25 d. 11-(3,17 $\beta$ -Dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide (ICI 164.384)



BF<sub>3</sub>·OEt<sub>2</sub> (195 ml) was added dropwise to a solution of 11-(3,17 $\beta$ -di(tetrahydropyranloxy)-6-keto-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide (6.87 g, 9.70 mmol) and HSiEt<sub>3</sub> (97 ml) in CH<sub>2</sub>Cl<sub>2</sub> (500 ml) at 0°C under N<sub>2</sub>. The reaction mixture was stirred over night at room temperature and was then slowly poored into aq. K<sub>2</sub>CO<sub>3</sub> (1000 ml, 1.0 M) at 0°C. Et<sub>2</sub>O (500 ml) was

added and after stirring for 30 min the organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 1:1) to give the title compound (3.91 g, 77%) as an oil.


$R_f$  (heptane-EtOAc, 1:1)=0.21

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.78 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz, 3H), 1.90 (bd,  $J=12$  Hz, 1H), 2.07-2.18 (m, 1H), 2.25-2.30 (m, 4H), 2.76 (d,  $J=16.8$ , 1H), 2.85 (dd,  $J=16.8, 5.0$  Hz, 1H), 2.93, 2.98 (2s, 3H), 3.26 (t,  $J=7.5$  Hz, 1H), 3.38 (m, 1H), 3.75 (broad t,  $J=7.5$  Hz, 1H), 6.41, 6.47 (2 bs, 1H), 6.59 (d,  $J=2.6$  Hz, 1H), 6.65 (dd,  $J=8.5, 2.6$  Hz, 1H), 7.13 (d,  $J=8.5$  Hz, 1H).

SM5

15 3,17 $\beta$ -Dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

a. 3,17 $\beta$ -Di(tetrahydropyranloxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene




Prepared as described for SM4-c using 3,17 $\beta$ -di(tetrahydropyranloxy)-6-keto-estra-1,3,5(10)-triene (4.79 g, 10.5 mmol) and 1-iodo-9-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-nonane (4.91 g, 11.0 mmol) as starting materials. The crude product was purified on column chromatography (heptane-EtOAc, 10:1) to give the title compound (3.8 g, 49%) as an oil.

$R_f$  (heptane-EtOAc, 1:1)=0.77

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.80, 0.82 (2s, 3H), 2.35 (m, 1H), 2.44 (m, 1H), 2.49 (t,  $J=7.4$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 2.70 (m, 1H), 3.50 (m, 1H), 3.61 (m, 1H), 3.74, 3.77 (2t,  $J=8$  Hz, 1H), 3.90 (m, 2H), 4.65, 4.68 (2m, 1H), 5.46 (m, 1H), 7.20 (d,  $J=8.6$  Hz, 1H), 7.31, 7.32 (2d,  $J=8.6$  Hz, 1H), 7.69 (broad s, 1H).

b. 3,17 $\beta$ -Dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene



Prepared as described for SM4-d using 3,17 $\beta$ -di(tetrahydropyranloxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (3.67 g, 4.75 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 2:1) to give the title compound (1.97 g, 70%) as an oil.


$R_f$  (heptane-EtOAc, 2:1)=0.32

15  $^1$ H NMR (CDCl<sub>3</sub>)  $\delta$  0.78 (s, 3H), 1.73 (m, 1H), 1.84-1.94 (m, 3H), 2.07-2.24 (m, 3H), 2.25-2.34 (m, 2H), 2.50 (t,  $J$ =7.4 Hz, 2H), 2.58 (t,  $J$ =7.0 Hz, 2H), 2.71 (d,  $J$ =16.8 Hz, 1H), 2.86 (dd,  $J$ =16.8, 5.0 Hz, 1H), 3.75 (t,  $J$ =8.5 Hz, 1H), 4.68 (broad s, 1H), 6.54 (d,  $J$ =2.6 Hz, 1H), 6.62 (dd,  $J$ =8.4, 2.6 Hz, 1H), 7.15 (d,  $J$ =8.4 Hz, 1H).

SM6


16 $\alpha$ - (Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-tetrahydropyranloxy-estra-1,3,5(10)-triene

a. 3-Hydroxy-17-methylene-estra-1,3,5(10)-triene



t-BuOK (31.4 g, 280 mmol) was added to a slurry of Ph<sub>3</sub>PCH<sub>3</sub>Br (100 g, 280 mmol) in dry toluene (350 ml) under N<sub>2</sub>. The temperature was raised to 100°C and the solution was stirred for 30 min. Estrone (25.0 g, 92.5 mmol) was then added in portions and the reaction mixture was stirred for 30 min. After cooling, acetone (30 ml) was added, the reaction mixture was stirred for 20 min and was then filtered through silica gel. The residue was purified on column chromatography (heptane-EtOAc, 3:1) to give the title compound (24.1 g, 97%) as white crystals.


$R_f$  (heptane-EtOAc, 2:1)=0.55  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.83 (s, 3H), 1.26 (m, 1H), 1.33-1.61 (m, 5H), 1.82 (m, 1H), 1.90-2.00 (m, 2H), 2.21 (td,  $J=11, 4$  Hz), 2.25-2.40 (m, 2H), 2.55 (m, 1H), 2.78-2.92 (m, 2H), 4.54 (s, 1H), 4.69 (m, 2H), 6.57 (d,  $J=2.7$  Hz, 1H), 6.64 (dd,  $J=8.4, 2.7$  Hz, 1H), 7.18 (d,  $J=8.4$  Hz, 1H).  
 5 b. 3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene 3-  
 O-benzoate



A solution of 3-hydroxy-17-methylene-estra-1,3,5(10)-triene (21.8 g, 81.2 mmol),  $\text{SeO}_2$  (300 mg, 2.70 mmol) and t-butylhydroperoxide (150 ml, 150 mmol, 1.0 M in toluene) was stirred over night. The product precipitated from the solution. Heptane (150 ml) was added and the slurry was stirred for 5 min. The precipitate (ca 20 g) was collected by filtration and was dissolved in  $\text{CH}_2\text{Cl}_2$  (500 ml). NaOH (aq., 500 ml, 1.0 M) and benzoylchloride (20.0 ml, 172 mmol) were added and the reaction mixture was vigorously stirred over night. The organic phase was dried ( $\text{Na}_2\text{SO}_4$ ), concentrated at reduced pressure and purified on column chromatography ( $\text{CH}_2\text{Cl}_2$ -EtOAc, 20:1) to give 20 the title compound (16.5 g, 52%) as white crystals.  
 25

$R_f$  (heptane-EtOAc, 1:1)=0.38  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.84 (s, 3H), 1.41-1.67 (m, 6H), 1.80-2.02 (m, 3H), 2.29-2.45 (m, 2H), 2.85-2.98 (m, 2H), 4.72 (broad s, 1H), 4.94 (d,  $J=2.1$  Hz, 1H), 5.09 (d,  $J=1.7$  Hz, 1H), 6.93 (d,  $J=2.5$  Hz, 1H), 6.97 (dd,  $J=8.5, 2.5$  Hz, 1H), 7.34 (d,  $J=8.5$  Hz, 1H), 7.50 (t,  $J=7.5$  Hz, 2H), 7.63 (tt,  $J=7.5, 1.3$  Hz, 1H), 8.20 (dd,  $J=7.5, 1.3$  Hz, 2H).  
 30

c. 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene 3-O-benzoate




CH<sub>2</sub>I<sub>2</sub> (53.6 g, 200 mmol) was added dropwise to a solution of ZnEt<sub>2</sub> (100 ml, 1.0 M in heptane, 100 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (250 ml) under N<sub>2</sub> at -10°C. The reaction mixture was stirred for 10 min at -10°C and then a solution of 3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene 3-O-benzoate (19.4 g, 50.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (125 ml) was slowly added dropwise.

The cooling bath was removed and the reaction mixture was stirred at ambient temperature for 3 h and then partitioned between Et<sub>2</sub>O (500 ml) and aq. HCl (400 ml, 0.5 M). The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was dissolved in EtOAc and precipitated with heptane and collected by filtration to give the title compound (18.6 g, 92%) as yellow crystals.

R<sub>f</sub> (heptane-EtOAc, 2:1)=0.29

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.42-0.60 (m, 3H), 0.70-0.76 (m, 1H), 0.84 (s, 3H), 2.27-2.36 (m, 2H), 2.85-2.98 (m, 2H), 4.20 (d, J=7.3 Hz, 1H), 6.93 (d, J=2.3 Hz, 1H), 6.97 (dd, J=8.4, 2.3 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 7.50 (t, J=7.6 Hz, 2H), 7.63 (t, J=7.6 Hz, 1H), 8.19 (d, J=7.6 Hz, 2H).

d. 16 $\alpha$ -(Dimethylhexyl)-silyloxy-17-(1,2-ethylene)-3-tetrahydropyranloxy-estra-1,3,5(10)-triene



35 Dimethylhexylchlorosilane (2.75 g, 15.4 mmol) was added to a solution of imidazole (2.19 g, 32.2 mmol) and 17-(1,2-ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene

3-O-benzoate (5.18 g, 12.9 mmol) in DMF (10 ml) and  $\text{CH}_2\text{Cl}_2$  (10 ml). The reaction mixture was stirred over night and was then partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with aq. HCl (0.5 M), water and brine, 5 dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure to give the crude  $16\alpha$ -O-silylether (7.22g).

$R_f$  (heptane-EtOAc, 10:1)=0.46

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.28-0.39 (m, 2H), 0.45-0.51 (m, 1H), 0.8 (m, 1H), 4.30 (d,  $J=8.3$  Hz, 1H).

10 The crude  $16\alpha$ -O-silylether (7.22g) was dissolved in THF (70 ml) and MeOH (30 ml). NaOH (aq., 30 ml, 1.0 M) was added and the reaction mixture was stirred for 1 h. The reaction mixture was partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water and brine, 15 dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 10:1) to give the free phenol (5.88g) contaminated by ca 4% methylbenzoate.

$R_f$  (heptane-EtOAc, 2:1)=0.52

20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.32 (m, 2H), 0.46 (m, 1H), 0.77 (m, 1H), 0.82 (s, 3H), 0.82 (s, 6H), 0.87, 0.88 (2d,  $J=6.9$  Hz, 6H), 2.18-2.28 (m, 2H), 2.75-2.88 (m, 2H), 4.29 (d,  $J=7.9$  Hz, 1H), 4.57 (s, 1H), 6.55 (d,  $J=2.7$  Hz, 1H), 6.61 (dd,  $J=8.4$ , 2.7 Hz, 1H), 7.13 (d,  $J=8.4$  Hz, 1H).

25 The free phenol (5.88g) was dissolved in  $\text{CH}_2\text{Cl}_2$  (20 ml). 2,3-Dihydropyran (2.0 ml, 21.9 mmol) and p-TSA (20 mg) was added and the reaction mixture was stirred for 30 min.  $\text{EtN}(\text{iPr})_2$  (0.1 ml) was added and the reaction mixture was concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 30:1) to give the title compound (6.65 g, 98%) as an oil.

$R_f$  (heptane-EtOAc, 10:1)=0.45

30  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.31 (m, 2H), 0.46 (m, 1H), 0.77 (m, 1H), 0.81 (s, 3H), 0.82 (s, 6H), 0.86, 0.88 (2s, 6H), 2.24 (m, 2H), 2.4 (m, 2H), 3.58 (m, 1H),


3.92 (m, 1H), 4.29 (d,  $J=8.0$  Hz, 1H), 5.38 (s, 1H), 6.78 (s, 1H), 6.83 (d,  $J=8.6$  Hz, 1H), 7.17 (d,  $J=8.6$  Hz, 1H).

Example 1

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-

5 7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide

a. 11-(3,17 $\beta$ -Dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate




Benzoyl chloride (500  $\mu$ L, 4.30 mmol) was added to a solution of 11-(3,17 $\beta$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide (1.13 g, 2.15 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 ml) and NaOH (10 ml, 1.0 M aq.). The reaction mixture was stirred over night and then partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure to give the title compound (1.36 g, quant.) as an oil.

$R_f$  (heptane-EtOAc, 1:1)=0.18

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.80 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz, 3H), 1.77 (m, 1H), 1.93 (m, 1H), 2.14 (m, 1H), 2.28 (m, 2H), 2.33-2.43 (m, 2H), 2.79 (d,  $J=17.0$  Hz, 1H), 2.89-2.98 (m, 1H), 2.90, 2.95 (2s, 3H), 3.24, 3.35 (2t,  $J=7.5$  Hz, 2H), 3.77 (broad t,  $J=8$  Hz, 1H), 6.93 (d,  $J=2.3$  Hz, 1H), 6.98 (dd,  $J=8.4$ , 2.3 Hz, 1H), 7.34 (d,  $J=8.4$  Hz, 1H), 7.51 (t,  $J=8$ , 2H), 7.63 (t,  $J=8$ , 1H), 8.19 (d,  $J=8$ , 2H).


b. 11-(3-Hydroxy-17-keto-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate



Pyridinium chlorochromate (PCC, 1.00 g, 4.64 mmol) was added in portions to a solution of 11-(3,17 $\beta$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate (1.36 g, 2.16 mmol) in 5  $\text{CH}_2\text{Cl}_2$  (15.0 ml) at 0°C under  $\text{N}_2$ . The cooling bath was removed and the reaction mixture was stirred at room temperature for 3 h.  $\text{Et}_2\text{O}$  (100 ml) was added and after 10 min stirring, the slurry was purified on column chromatography ( $\text{Et}_2\text{O}$ ) to give the title compound (1.22 g, 90%) as 10 an oil.

$R_f$  (heptane-EtOAc, 1:1)=0.36


$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.92, 0.95 (2t,  $J=7.4$  Hz, 3H), 0.92 (s, 3H), 1.81 (dt,  $J=2.4, 11$  Hz, 1H), 1.87-2.02 (m, 3H), 2.18 (dt,  $J=19, 8.5$  Hz, 1H), 2.28 (m, 2H), 2.40-2.51 (m, 3H), 15 2.85 (d,  $J=16.9$  Hz, 1H), 2.90, 2.95 (2s, 3H), 2.94-3.02 (m, 1H), 3.24, 3.35 (2t,  $J=7.5$  Hz, 2H), 6.95 (d,  $J=2.3$  Hz, 1H), 7.00 (dd,  $J=8.5, 2.3$  Hz, 1H), 7.34 (d,  $J=8.5$  Hz, 1H), 7.51 (t,  $J=7.5$ , 2H), 7.63 (t,  $J=7.5$ , 1H), 8.19 (d,  $J=7.5$ , 2H). 20 c. 11-(3-Hydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide



$t\text{-BuOK}$  (112 mg, 1.00 mmol) was added to a solution of  $\text{Ph}_3\text{PCH}_3\text{Br}$  (357 mg, 1.00 mmol) in dry DMSO (1.0 ml) under  $\text{N}_2$ . The temperature was raised to 120°C and a solution of 11-(3-hydroxy-17-keto-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate (207 mg, 0.330 mmol) in dry DMSO (0.5 ml) was added. The reaction mixture was stirred for 30 min, cooled and partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was 30 washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on 35

column chromatography (heptane-EtOAc, 2:1) to give the title compound (157 mg, 76%) as an oil.

5  $R_f$  (heptane-EtOAc, 2:1) = 0.20  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.82 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz, 3H), 1.92 (bd,  $J=11.9$  Hz, 1H), 2.25-2.40 (m, 5H), 2.42-  
10 2.59 (m, 1H), 2.71 (d,  $J=16.7$  Hz, 1H), 2.87 (dd,  $J=16.7$ , 5.0 Hz, 1H), 2.93, 2.98 (2s, 3H), 3.26 (t,  $J=7.6$  Hz, 1H), 3.38 (m, 1H), 4.67 (broad s, 2H), 6.53, 6.58 (2 broad s, 1H), 6.60 (d,  $J=2.5$  Hz, 1H), 6.66 (dd,  $J=8.4$ , 2.5 Hz, 1H), 7.14 (d,  $J=8.4$  Hz, 1H).  
d. 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide




A mixture of 11-(3-hydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide (232 mg, 0.445 mmol),  $\text{SeO}_2$  (15 mg, 0.14 mmol) and 20  $t$ -butylhydroperoxide (1.00 ml, 1.00 mmol, 1.0 M in toluene) was stirred for 4 h. The reaction mixture was then partitioned between  $\text{Et}_2\text{O}$  (30 ml) and aq.  $\text{FeSO}_4$  (0.5 M, 5 ml). The organic phase was washed with water and brine, 25 dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 2:1) to give the title compound (127 mg, 53%) as an oil.

30  $R_f$  (heptane-EtOAc, 1:1) = 0.38  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.83 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz, 3H), 2.27-2.42 (m, 4H), 2.72 (d,  $J=16.7$  Hz, 1H), 2.86 (dd,  $J=16.7$ , 5.0 Hz, 1H), 2.93, 2.98 (2s, 3H), 3.26 (t,  $J=7.6$  Hz, 1H), 3.38 (m, 1H), 4.72 (broad t, 1H), 4.91 (d,  $J=2.0$  Hz, 1H), 5.08 (d,  $J=1.5$  Hz, 1H), 6.61 (d,  $J=2.6$  Hz, 1H), 35 6.66 (dd,  $J=8.3$ , 2.6 Hz, 1H), 6.71, 6.75 (2 bs, 1H), 7.13 (d,  $J=8.3$  Hz, 1H).

Example 2

11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate

5



Benzoyl chloride (100  $\mu$ L, 0.861 mmol) was added to a  
 10 solution of 11-(3,16 $\alpha$ -dihydroxy-17-methylene-estra-  
 1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-  
 15 amide (106 mg, 0.20 mmol) in  $\text{CH}_2\text{Cl}_2$  (1.0 ml) and NaOH (1.0  
 ml, 1.0 M aq.). The reaction mixture was stirred for 9 h  
 and then partitioned between  $\text{Et}_2\text{O}$  and water. The organic  
 phase was dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pres-  
 sure. The residue was purified on column chromatography  
 (heptane-EtOAc, 1:1) to give the title compound (124 mg,  
 98%) as an oil.


$R_f$  (heptane-EtOAc, 1:1)=0.42

20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.84 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz,  
 3H), 2.28 (m, 2H), 2.40-2.52 (m, 2H), 2.81 (d,  $J=16.7$  Hz,  
 1H), 2.90, 2.96 (2s, 3H), 2.95 (dd,  $J=16.7$ , 5.7 Hz, 1H),  
 3.24, 3.35 (2t,  $J=7.6$  Hz, 2H), 4.74 (broad d,  $J=6.6$  Hz,  
 1H), 4.93 (d,  $J=1.9$  Hz, 1H), 5.10 (d,  $J=1.5$  Hz, 1H), 6.93  
 25 (d,  $J=2.3$  Hz, 1H), 6.99 (dd,  $J=8.5$ , 2.3 Hz, 1H), 7.35 (d,  
 $J=8.5$  Hz, 1H), 7.50 (t,  $J=7.4$  Hz, 2H), 7.63 (t,  $J=7.4$  Hz,  
 1H), 8.19 (d,  $J=7.4$  Hz, 2H).

Example 3

30 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate

35



ZnEt<sub>2</sub> (1.0 ml, 1.0 M in heptane, 1.0 mmol) was added dropwise to a solution of  $\text{CH}_2\text{I}_2$  (340 mg, 1.27 mmol) in

$\text{CH}_2\text{Cl}_2$  (2.5 ml) under  $\text{N}_2$  at -10°C. The reaction mixture was stirred for 10 min at -10°C and then a solution of 11-(3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate

5 (124 mg, 0.193 mmol) in  $\text{CH}_2\text{Cl}_2$  (1.0 ml) was added. The cooling bath was removed and the reaction mixture was stirred at ambient temperature for 5 h and then partitioned between  $\text{Et}_2\text{O}$  (10 ml) and aq. HCl (3 ml, 1.0 M). The organic phase was washed with water and brine, dried 10 ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 2:1, 1:1) to give the title compound (84 mg, 66%) as an oil.


$R_f$  (heptane-EtOAc, 1:1)=0.50

15  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.46-0.52 (m, 2H), 0.54-0.61 (m, 1H), 0.73-0.79 (m, 1H), 0.84 (s, 3H), 0.92, 0.95 (2t,  $J=7.3$  Hz, 3H), 2.24-2.37 (m, 3H), 2.41-2.50 (m, 1H), 2.80 (d,  $J=16.6$  Hz, 1H), 2.90, 2.95 (2s, 3H), 2.91-2.98 (m, 1H), 3.24, 3.35 (2t,  $J=7.5$  Hz, 2H), 4.22 (broad s, 1H), 6.93 (d,  $J=2$  Hz, 1H), 6.97 (dd,  $J=8.6$ , 2 Hz, 1H), 7.32 (d,  $J=8.6$  Hz, 1H), 7.50 (t,  $J=7.4$  Hz, 2H), 7.63 (t,  $J=7.4$  Hz, 1H), 8.19 (d,  $J=7.4$  Hz, 2H).

20

Example 4

25 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide



30 LiOH (1.0 ml, 1.0 M in 50% aq. MeOH, 1.0 mmol) was added to a solution of 11-(17-(1,2-ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate (84 mg, 0.128 mmol) in THF (2.0 ml). The reaction mixture was stirred for 30 min and was then partitioned between  $\text{Et}_2\text{O}$  (10 ml) and aq. HCl (1.5 ml, 1.0 M) and brine (2 ml). The organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concen-

35

trated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 2:1, 1:1) to give the title compound (70 mg, 99%) as an oil.

$R_f$  (heptane-EtOAc, 1:1)=0.41

5      $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.45-0.51 (m, 2H), 0.53-0.59 (m, 1H), 0.70-0.77 (m, 1H), 0.82 (s, 3H), 0.92, 0.95 (2t, J=7.3 Hz, 3H), 1.82-2.00 (m, 2H), 2.24-2.41 (m, 4H), 2.72 (d, J=16.6 Hz, 1H), 2.86 (dd, J=16.6, 4.9 Hz, 1H), 2.93, 2.98 (2s, 3H), 3.26 (t, J=7.7 Hz, 1H), 3.37 (m, 1H), 4.20 (broad t, J=6 Hz, 1H), 6.36, 6.42 (2s, 1H), 6.60 (d, J=2.3 Hz, 1H), 6.64 (dd, J=8.4, 2.3 Hz, 1H), 7.12 (d, J=8.4 Hz, 1H).


Example 5

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-

15    pentafluoro-n-pentyl) sulfinyl]nonyl]-estra-1,3,5(10)-triene

a. 3,17 $\beta$ -Dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene 3-O-benzoate

20




Prepared as described for Example 1-a using 3,17 $\beta$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (250 mg, 0.423 mmol) as starting material to give the title compound (275 mg, 94%) as an oil.

$R_f$  (heptane-EtOAc, 2:1)=0.38

30     $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.80 (s, 3H), 1.77 (m, 1H), 1.83-1.97 (m, 3H), 2.09-2.24 (m, 3H), 2.34-2.44 (m, 2H), 2.50 (t, J=7.4 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 2.79 (d, J=16.8 Hz, 1H), 2.94 (dd, J=16.8, 4.7 Hz, 1H), 3.76 (t, J=8.5 Hz, 1H), 6.93 (d, J=2.4 Hz, 1H), 6.98 (dd, J=8.4, 2.4 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.51 (t, J=8 Hz, 2H), 7.63 (t, J=8 Hz, 1H), 8.19 (d, J=8 Hz, 2H).

b. 3-Hydroxy-17-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene 3-O-benzoate




Pyridinium chlorochromate (PCC, 172 mg, 0.800 mmol) was added in portions to a solution of 3,17 $\beta$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene 3-O-benzoate (272 mg, 0.391 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 ml) at 0°C under N<sub>2</sub>. The reaction mixture was stirred at 0°C for 10 min, then at room temperature for 1 h. Et<sub>2</sub>O (10 ml) was added and after 5 min stirring, the slurry was purified on column chromatography (Et<sub>2</sub>O) to give the title compound (229 mg, 85%) as an oil.

R<sub>f</sub> (heptane-EtOAc, 2:1)=0.56

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.92 (s, 3H), 2.08-2.24 (m, 3H), 2.40-2.61 (m, 7H), 2.85 (d, J=16.5 Hz, 1H), 2.98 (dd, J=16.5, 5.6 Hz, 1H), 6.95 (d, J=2.2 Hz, 1H), 7.00 (dd, J=8.4, 2.2 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.51 (t, J=7.5 Hz, 2H), 7.64 (t, J=7.5 Hz, 1H), 8.19 (d, J=7.5 Hz, 2H).

c. 3-Hydroxy-17-methylene-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

25




30 t-BuOK (862 mg, 7.68 mmol) was added to a solution of Ph<sub>3</sub>PCH<sub>3</sub>Br (2.74 g, 7.68 mmol) in dry DMSO (8.0 ml) under N<sub>2</sub>. The temperature was raised to 110°C during 20 min. This solution was then added portionwise during 5 min to 3-hydroxy-17-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene 3-O-benzoate (532 mg, 0.768 mmol) at 110°C under N<sub>2</sub>. The reaction mixture was stirred for another 5 min, cooled and parti-

tioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water acidified with 1M HCl (ca 10 ml) and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 10:1) to give the title compound (162 mg, 36%) as an oil.

$R_f$  (heptane-EtOAc, 5:1)=0.33

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.82 (s, 3H), 2.17 (m, 2H), 2.50 (t,  $J=7.4$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 2.72 (d,  $J=16.9$  Hz, 1H), 2.88 (dd,  $J=16.9$ , 5.3 Hz, 1H), 4.67 (broad s, 2H), 6.55 (d,  $J=2.6$  Hz, 1H), 6.63 (dd,  $J=8.5$ , 2.6 Hz, 1H), 7.17 (d,  $J=8.5$  Hz, 1H).

d. 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene



A mixture of 3-hydroxy-17-methylene-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (157 mg, 0.268 mmol),  $\text{SeO}_2$  (5 mg, 0.045 mmol) and t-butylhydroperoxide (1.00 ml, 1.00 mmol, 1.0 M in toluene) was stirred for 30 h. The reaction mixture was purified on column chromatography (heptane-EtOAc, 5:1, 3:1, 2:1, 1:2, 1:3) to give the title compound (63 mg, 38%) as an oil.


$R_f$  (heptane-EtOAc, 1:3)=0.27

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.83 (s, 3H), 1.94 (broad d,  $J=8.4$  Hz, 1H), 2.10-2.32 (m, 6H), 2.59-2.83 (m, 5H), 2.87 (dd,  $J=16.8$ , 5.2 Hz, 1H), 4.72 (broad d,  $J=6.1$  Hz, 1H), 4.92 (d,  $J=2.0$  Hz, 1H), 5.07 (d,  $J=1.7$  Hz, 1H), 5.9, 6.2 (2 broad s, 1H), 6.57 (d,  $J=2.4$  Hz, 1H), 6.64 (m, 1H), 7.14 (d,  $J=8.3$  Hz, 1H).

Example 6

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-benzoate

5



Prepared as described for Example 1-a using 3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene (50 mg, 0.081 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:1, 1:2) to give the title compound (33 mg, 56%) as an oil.

15  $R_f$  (heptane-EtOAc, 1:3)=0.32

10  $^1H$  NMR ( $CDCl_3$ )  $\delta$  0.84 (s, 3H), 2.10-2.32 (m, 6H), 2.37-2.52 (m, 2H), 2.60-2.77 (m, 4H), 2.80 (d,  $J=16.4$  Hz, 1H), 2.96 (dd,  $J=16.4$ , 5.2 Hz, 1H), 4.73 (broad d,  $J=5.4$  Hz, 1H), 4.93 (d,  $J=1.9$  Hz, 1H), 5.09 (d,  $J=1.4$  Hz, 1H), 6.93 (d,  $J=2.3$  Hz, 1H), 6.99 (dd,  $J=8.6$ , 2.3 Hz 1H), 7.35 (d,  $J=8.6$  Hz, 1H), 7.51 (t,  $J=8$  Hz, 2H), 7.63 (t,  $J=8$  Hz, 1H), 8.19 (d,  $J=8$  Hz, 2H).


20

Example 7

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

25 a. 16 $\alpha$ -(Dimethylthexyl)-silyloxy-17-(1,2-ethylene)-6-keto-3-tetrahydropyranloxy-estra-1,3,5(10)-triene

30




Prepared as described for SM4-b using 16 $\alpha$ -(dimethylthexyl)-silyloxy-17-(1,2-ethylene)-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (6.62 g, 12.6 mmol) as starting material. The 6-hydroxy derivative (7.01 g, quant.,  $R_f$  (heptane-EtOAc, 5:1)=0.15, contained 20%

starting material by NMR). The crude 6-keto product was purified on column chromatography (heptane-EtOAc, 10:1) to give the title compound (4.60 g, 68 %) as a syrup.

$R_f$  (heptane-EtOAc, 3:1)=0.51

5      $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.06 (2s, 6H), 0.35 (m, 2H), 0.48 (m, 1H), 0.80 (m, 1H), 0.82 (s, 3H), 0.82 (s, 6H), 0.87, 0.88 (2d,  $J=6.8$  Hz, 6H), 2.00 (m, 1H), 2.24-2.37 (m, 2H), 2.52 (m, 1H), 2.75 (dd,  $J=15.8, 2.1$  Hz, 1H), 3.60 (m, 1H), 3.88 (m, 1H), 4.28 (d,  $J=7.8$  Hz, 1H), 5.47 (m, 1H),  
10    7.22 (dd,  $J=8.6, 2.7$  Hz, 1H), 7.33 (d,  $J=8.6$  Hz, 1H), 7.72, 7.72 (2d,  $J=2.7$  Hz, 1H).  
b. 16 $\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7 $\alpha$ -[9-(4,4,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene

15




Prepared as described for SM4-c using 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (4.60 g, 8.54 mmol) and 1-iodo-9-(4,4,5,5-pentafluoro-pentylsulfonyl)-nonane (4.78 g, 10.7 mmol) as starting materials. The crude product was purified on column chromatography (heptane-EtOAc, 20:1) to give the title compound (4.13 g, 56%) as an oil.

$R_f$  (heptane-EtOAc, 10:1)=0.27

1 $H$  NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.36 (m, 2H), 0.49 (m, 1H), 0.80 (m, 1H), 0.81 (s, 3H), 0.83 (s, 6H), 0.88 (d,  $J=6.8$  Hz, 6H), 2.17 (m, 2H), 2.34 (m, 1H), 2.44-2.50 (m, 1H), 2.49 (t,  $J=7.3$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 2.75 (td,  $J=10.4, 3.8$  Hz, 1H), 3.61 (m, 1H), 3.91 (m, 1H), 4.23 (d,  $J=7.4$  Hz, 1H), 5.46 (m, 1H), 7.20 (dd,  $J=8.5, 2.4$  Hz, 1H), 7.30 (d,  $J=8.5$  Hz, 1H), 7.69 (d,  $J=2.4$  Hz, 1H).

c.  $16\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\alpha$ -hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene

5




NaBH<sub>4</sub> (285 mg, 7.53 mmol) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (2.85 g, 3.32 mmol) in MeOH (14.0 ml) and THF (7.0 ml). The reaction mixture was stirred over night and was then partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 10:1,5:1) to give the title compound (2.85 g, quant.) as an oil.

*R*<sub>f</sub> (heptane-EtOAc, 5:1)=0.18

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.33 (m, 2H), 0.48 (m, 1H), 0.80 (m, 1H), 0.81 (s, 6H), 0.83 (s, 6H), 0.88, 0.88 (2d, J=6.8 Hz, 6H), 2.09-2.28 (m, 3H), 2.43 (td, J=11, 4 Hz, 1H), 2.49 (t, J=7.3 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 3.60 (m, 1H), 3.93 (m, 1H), 4.23 (d, J=7.9 Hz, 1H), 4.88 (m, 1H), 5.40, 5.43 (2t, J=3 Hz, 1H), 6.91 (m, 1H), 7.16 (d, J=8.6 Hz, 1H), 7.33 (d, J=2.5 Hz, 1H).  
25 d.  $16\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\beta$ -fluoro-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene

30



35 Diethylaminosulfurtrifluoride (DAST, 150  $\mu$ l, 1.13 mmol) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\alpha$ -hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-


5 estra-1,3,5(10)-triene (780 mg, 0.908 mmol) in  $\text{CH}_2\text{Cl}_2$  (5.0 ml). The reaction mixture was stirred for 5 min, concentrated at reduced pressure and purified on column chromatography (heptane-EtOAc, 10:1) to give the title compound (629 mg, 80%) as an oil.

5  $R_f$  (heptane-EtOAc, 10:1)=0.41

10  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.35 (m, 2H), 0.47 (m, 1H), 0.79 (m, 1H), 0.83 (s, 6H), 0.84 (s, 3H), 0.88, 0.88 (2d,  $J=6.8$  Hz, 6H), 2.17 (m, 2H), 2.31 (m, 2H), 2.50 (t,  $J=7.3$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 3.61 (m, 1H), 3.92 (m, 1H), 4.25 (d,  $J=7.2$  Hz, 1H), 5.27, 5.28 (2d,  $J_{\text{H},\text{F}}=51$  Hz, 1H), 5.39, 5.42 (2t,  $J=3.1$  Hz, 1H), 7.00-7.09 (m, 2H), 7.25 (d,  $J=8$  Hz, 1H).

15 e. 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estr-1,3,5(10)-triene

20




25 A solution of pyridiniumtosylate in MeOH (0.10 ml, 1.0 M) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\beta$ -fluoro-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranoyloxy-estra-1,3,5(10)-triene (248 mg, 0.288 mmol) in MeOH (2.0 ml) and  $\text{CHCl}_3$  (2.0 ml). The reaction mixture was stirred for 48 h and was then partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 3:1, 1:1) to give the title compound (95 mg, 51%).

30  $R_f$  (heptane-EtOAc, 3:1)=0.10

35  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.46-0.60 (m, 3H), 0.73 (m, 1H), 0.86 (s, 3H), 1.67 (m, 1H), 1.83-2.05 (m, 6H), 2.09-2.32 (m, 4H), 2.50 (t,  $J=7.4$  Hz, 2H), 2.59 (t,  $J=7.1$  Hz, 2H), 3.44 (s, 3H), 3.98 (d,  $J=1.6$  Hz, 1H), 4.23 (t,  $J=7.2$  Hz, 1H), 4.78 (s, 1H), 6.70-6.74 (m, 2H), 7.16 (d,  $J=8.0$  Hz, 1H).

MS-ESI  $[M-H_2O+H]^+$  = 629Example 8

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-[  
 5 (4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-  
 1,3,5(10)-triene



10 A solution of NaIO<sub>4</sub> in MeOH (0.50 ml, 0.25 mmol, 0.50 M) was added to a solution of 17-(1,2-ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (79 mg, 0.122 mmol) in MeOH (3.0 ml). The reaction mixture was stirred 15 over night, concentrated at reduced pressure and partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 1:2, 1:3) to give the title compound (70 mg, 86%).

20 R<sub>f</sub> (heptane-EtOAc, 1:3) = 0.20


<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.45-0.59 (m, 3H), 0.73 (m, 1H), 0.85 (s, 3H), 2.11-2.32 (m, 6H), 2.59-2.84 (m, 4H), 3.42 (s, 3H), 3.98 (s, 1H), 4.22 (broad t, J=7 Hz, 1H), 6.31, 6.51 (2s, 1H), 6.73 (m, 2H), 7.15 (m, 1H).

25 MS-ESI  $[M-H_2O+H]^+$  = 645

Example 9

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene


30 a. 16 $\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-hydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)-thiononyl]-estra-1,3,5(10)-triene



A solution of pyridiniumtosylate in MeOH (0.10 ml, 1.0 M) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-5 estra-1,3,5(10)-triene (160 mg, 0.187 mmol) in MeOH (2.0 ml) and THF (0.5 ml). The reaction mixture was stirred over night, concentrated at reduced pressure and purified on column chromatography (heptane-EtOAc, 10:1, 5:1) to give the title compound (100 mg, 69%).

10  $R_f$  (heptane-EtOAc, 3:1)=0.38

11  $^1H$  NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.37 (m, 2H), 0.49 (m, 1H), 0.80 (m, 1H), 0.81 (s, 3H), 0.83 (s, 6H), 0.89 (d, J=6.9 Hz, 6H), 1.97-2.24 (m, 4H), 2.33 (m, 1H), 2.45-2.50 (m, 1H), 2.49 (t, J=7.5 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 2.74 (td, J=11, 4 Hz, 1H), 4.24 (d, J=7.9 Hz, 1H), 5.61 (broad s, 1H), 7.05 (dd, J=8.6, 2.8 Hz, 1H), 7.28 (d, J=8.6 Hz, 1H), 7.56 (d, J=2.8 Hz, 1H).  
15 b. 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-20,1,3,5(10)-triene



25 16 $\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-hydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)-thiononyl]-estra-1,3,5(10)-triene (100 mg, 0.129 mmol) was dissolved in a solution of tetrabutylammoniumfluoride trihydrate in THF (0.5 ml, 1.0 M). The reaction mixture was stirred over night at 50°C and was then partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 3:1) to give the title compound (70 mg, 86%).  
30 35  $R_f$  (heptane-EtOAc, 2:1)=0.35


<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.47-0.62 (m, 3H), 0.78 (m, 1H), 0.82 (s, 3H), 2.02-2.24 (m, 4H), 2.35 (m, 1H), 2.46-2.52 (m, 1H), 2.49 (t, J=7.4 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 2.76 (m, 1H), 4.24 (t, J=6.7 Hz, 1H), 6.40 (s, 1H), 7.06 (dd, J=8.5, 2.9 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 7.61 (d, J=2.9 Hz, 1H).

MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=613

Example 10

17-(1,2-Ethylene)-3,16α-dihydroxy-6-keto-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene

15



Prepared as described for Example 8 using 17-(1,2-ethylene)-3,16α-dihydroxy-6-keto-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (65 mg, 0.103 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:2, 1:3) to give the title compound (46 mg, 69%).

R<sub>f</sub> (heptane-EtOAc, 1:3)=0.23


<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.47-0.61 (m, 3H), 0.77 (m, 1H), 0.82 (s, 3H), 2.47 (broad d, J=11 Hz, 1H), 2.62-2.93 (m, 5H), 4.23 (broad t, J=7 Hz, 1H), 7.03 (m, 1H), 7.25 (d, J=8 Hz, 1H), 7.47-7.55 (m, 2H).

MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=629

Example 11

17-(1,2-Ethylene)-3,6α,16α-trihydroxy-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene  
a. 1α-(Dimethylhexyl)-silyloxy-17-(1,2-ethylene)-3,6α-dihydroxy-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

35




NaBH<sub>4</sub> (20 mg, 0.53 mmol) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (181 mg, 0.211 mmol) in MeOH (1.0 ml) and THF (0.5 ml). The reaction mixture was stirred for 30 min. A solution of pyridinium-tosylate in MeOH (1.0 M, 3.0 ml) was added and the reaction mixture was stirred over night and was then partitioned between Et<sub>2</sub>O and water. The organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure. The residue was purified on column chromatography (heptane-EtOAc, 2:1) to give the title compound (114 mg, 70%).

R<sub>f</sub> (heptane-EtOAc, 3:1)=0.25

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.34 (m, 2H), 0.47 (m, 1H), 0.80 (m, 1H), 0.82 (s, 3H), 0.83 (s, 6H), 0.88, 0.88 (2d, J=6.9 Hz, 6H), 1.79 (d, J=8.2 Hz, 1H), 1.81-1.96 (m, 4H), 1.99 (m, 1H), 2.09-2.26 (m, 3H), 2.41 (td, J=11, 4 Hz, 1H), 2.49 (t, J=7.4 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 4.23 (d, J=7.9 Hz, 1H), 4.87 (s, 1H), 4.88 (m, 1H), 6.70 (dd, J=8.4, 2.8 Hz, 1H), 7.07 (d, J=8.4 Hz, 1H), 7.14 (d, J=2.8 Hz, 1H).

20 b. 17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

25



30 Prepared as described for Example 9-b using 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3,6 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (94 mg, 0.121 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 2:1) to give the title compound (62 mg, 81%).

35

R<sub>f</sub> (heptane-EtOAc, 2:1)=0.22


<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.47-0.60 (m, 3H), 0.74 (m, 1H), 0.83 (s, 3H), 1.63 (td, J=11, 2 Hz, 1H), 1.71 (m, 1H), 1.79 (d, J=8.0 Hz, 1H), 1.83-2.04 (m, 4H), 2.09-2.28 (m, 3H), 2.42 (td, J=11, 4 Hz, 1H), 2.49 (t, J=7.4 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 4.22 (t, J=7.3 Hz, 1H), 4.87 (s, 1H), 4.90 (broad t, J=6.4 Hz, 1H), 6.71 (dd, J=8.3, 2.7 Hz, 1H), 7.2 (d, J=8.3 Hz, 1H), 7.14 (d, J=2.7 Hz, 1H).

MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=615

Example 12

10 17-(1,2-Ethylene)-3,6α,16α-trihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-1,3,5(10)-triene

15



Prepared as described for Example 8 using 17-(1,2-ethylene)-3,6α,16α-trihydroxy-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (54 mg, 0.085 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:3, 1:5) to give the title compound (56 mg, quant.).

R<sub>f</sub> (heptane-EtOAc, 1:3)=0.15


15 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.44-0.59 (m, 3H), 0.75 (m, 1H), 0.83 (s, 3H), 2.41 (broad t, J=11.5 Hz, 1H), 2.60-2.83 (m, 4H), 4.21 (broad s, 1H), 4.89 (broad t, J=6 Hz, 1H), 6.48, 6.56 (2s, 1H), 6.70 (dd, J=8.5, 2.3 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 7.16 (d, J=2.3 Hz, 1H).

MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=631

Example 13

30 17-(1,2-Ethylene)-3,16α-dihydroxy-6α-methoxy-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene


a. 16α-(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6α-methoxy-7α-[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene



5        NaH (20 mg, 0.62 mmol) was added to a solution of  
10      16α-(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6α-  
15      hydroxy-7α-[9-(4,4,5,5-pentafluoro-n-pentyl)thiononyl]-  
20      3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (232 mg,  
25      0.270 mmol) in THF (2.0 ml) under N<sub>2</sub>. MeI (0.150 ml, 2.41  
mmol) was added and the reaction mixture was stirred for  
4 h, diluted with Et<sub>2</sub>O and then filtered through silica  
gel. The filtrate was concentrated at reduced pressure to  
give the title compound (205 mg, 87%).

R<sub>f</sub> (heptane-EtOAc, 3:1)=0.61

15      <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.01, 0.09 (2s, 6H), 0.34 (m, 2H), 0.48  
(m, 1H), 0.80 (m, 1H), 0.82 (s, 3H), 0.83 (s, 6H), 0.89,  
0.89 (2d, J=6.8 Hz, 6H), 2.45 (td, J=11, 4 Hz, 1H), 2.49  
(t, J=7.5 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 3.56, 3.56  
(2s, 3H), 3.59 (m, 1H), 3.93 (m, 1H), 4.25 (d, J=6.7 Hz,  
2H), 4.35 (m, 1H), 5.36, 5.50 (2t, 3 Hz, 1H), 6.89, 6.93  
1H), 7.14 (d, J=8.6 Hz, 1H), 7.28  
(2dd, J=8.6, 2.8 Hz, 1H), 7.28 (s, 1H).  
b. 16α-(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-  
hydroxy-6α-methoxy-7α-[9-(4,4,5,5-pentafluoro-n-  
pentyl)thiononyl]-estra-1,3,5(10)-triene




30      Pyridiniumtosylate (15 mg) was added to a solution  
35      of 16α-(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6α-  
methoxy-7α-[9-(4,4,5,5-pentafluoro-n-pentyl)thiononyl]-  
3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (205 mg,  
0.235 mmol) in EtOH (2.0 ml). The reaction mixture was  
stirred over night, concentrated at reduced pressure,

redissolved in  $\text{Et}_2\text{O}$  and then filtered through silica gel. The filtrate was concentrated at reduced pressure to give the title compound (178 mg, 96%).

$R_f$  (heptane-EtOAc, 3:1)=0.49

5  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.08 (2s, 6H), 0.34 (m, 2H), 0.48 (m, 1H), 0.80 (m, 1H), 0.82 (s, 3H), 0.83 (s, 6H), 0.88, 0.89 (2d,  $J=6.8$  Hz, 6H), 2.09-2.26 (m, 4H), 2.43 (broad t,  $J=12$  Hz, 1H), 2.49 (t,  $J=7.4$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 3.57 (s, 3H), 4.25 (d,  $J=7.5$  Hz, 1H), 4.34 (d, 10  $J=4.5$  Hz, 1H), 4.64 (s, 1H), 6.68 (dd,  $J=8.7$ , 2.7 Hz, 1H), 7.07 (d,  $J=2.7$  Hz, 1H), 7.11 (d,  $J=8.7$  Hz, 1H).  
 10 c. 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-(4,4,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

15




Prepared as described for Example 9-b using 16 $\alpha$ -  
 20 (dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-hydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-(4,4,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (178 mg, 0.226 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 5:1, 3:1) to give the title compound (118 mg, 81%).

$R_f$  (heptane-EtOAc, 3:1)=0.29

1  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.47-0.60 (m, 3H), 0.74 (m, 1H), 0.83 (s, 3H), 2.09-2.28 (m, 4H), 2.43 (td,  $J=11.0$ , 3.8 Hz, 1H), 2.49 (t,  $J=7.4$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 3.57 (s, 3H), 4.22 (t,  $J=7.4$  Hz, 1H), 4.36 (d,  $J=5.0$  Hz, 1H), 4.72 (s, 1H), 6.68 (dd,  $J=8.4$ , 2.6 Hz, 1H), 7.08 (d,  $J=2.6$  Hz, 1H), 7.11 (d,  $J=8.4$  Hz, 1H).  
 30 MS-ESI  $[\text{M}-\text{H}_2\text{O}+\text{H}]^+=629$

Example 14

35 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene




5        Prepared as described for Example 8 using 17-(1,2-ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (110 mg, 0.170 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:2) to give the title compound (94 mg, 83%).  
10       $R_f$  (heptane-EtOAc, 1:2)=0.27  
 $^1$ H NMR ( $CDCl_3$ )  $\delta$  0.46-0.60 (m, 3H), 0.74 (m, 1H), 0.83 (s, 3H), 1.87-2.04 (m, 2H), 2.11-2.32 (m, 6H), 2.42 (broad t,  $J$ =12 Hz, 1H), 2.60-2.83 (m, 4H), 3.55 (s, 3H), 4.21 (t,  $J$ =7.5 Hz, 1H), 4.36 (broad s, 1H), 5.62, 5.87 (2s, 1H), 6.68 (broad d,  $J$ =8.5, 1H), 7.10 (m, 2H).  
15      MS-ESI  $[M-H_2O+H]^+$ =645

Example 15

17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

a. 16 $\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\beta$ -fluoro-3-hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)-thiononyl]-estra-1,3,5(10)-triene  
25




30        A solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\beta$ -fluoro-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (380 mg, 0.441 mmol) in THF (10 ml) and  $H_2SO_4$  (aq. 1.0 M, 1.0 ml) was stirred for 5 h and was then partitioned between  $Et_2O$  and  $NaHCO_3$  (aq.sat.). The organic phase was washed with brine, dried ( $Na_2SO_4$ ) and concentrated at

reduced pressure to give the crude title compound (390 mg).

$R_f$  (heptane-EtOAc, 3:1)=0.42

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.35 (m, 2H), 0.48 5 (m, 1H), 0.79 (m, 1H), 0.83 (s, 6H), 0.84 (s, 3H), 0.88, 0.88 (2d, J=6.9 Hz, 6H), 2.50 (t, J=7.4 Hz, 2H), 2.60 (t, J=7.0 Hz, 2H), 4.26 (d, J=7.4 Hz, 1H), 4.71 (s, 1H), 5.24 (dd, J<sub>H,F</sub>=51, 1.8 Hz, 1H), 6.79-6.86 (m, 2H), 7.22 (d, J=8.4 Hz, 1H).

10 b. 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene



Prepared as described for Example 9-b using 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\beta$ -fluoro-3-hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (377 mg) as starting material. The reaction mixture was stirred for 50 h. The crude product was purified on column chromatography (heptane-EtOAc, 5:1, 3:1) to give the title compound (120 mg, 44% in 2 steps).


25  $R_f$  (heptane-EtOAc, 3:1)=0.2

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.47-0.60 (m, 3H), 0.75 (m, 1H), 0.86 (s, 3H); 1.67 (m, 1H), 1.83-2.25 (m, 8H), 2.25-2.38 (m, 2H), 2.50 (t, J=7.4 Hz, 2H), 2.59 (t, J=7.0 Hz, 2H), 4.24 (t, J=6.8 Hz, 1H), 4.82 (s, 1H), 5.26 (dd, J<sub>H,F</sub>=51, 2 Hz, 1H), 6.80-6.86 (m, 2H), 7.22 (d, J=8.1 Hz, 1H).

30 MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=617

Example 16


17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl-estra-1,3,5(10)-triene



5       Prepared as described for Example 8 using 17-(1,2-ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (71 mg, 0.112 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:2, 1:3) to give the title compound (56 mg, 77%).  
10      R<sub>f</sub> (heptane-EtOAc, 1:3)=0.28  
<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.47-0.60 (m, 3H), 0.74 (m, 1H), 0.86 (s, 3H), 2.59-2.85 (m, 4H), 4.23 (t, J=6.7 Hz, 1H), 5.26 (d, J<sub>H,F</sub>=51 Hz, 1H), 6.32, 6.59 (2s, 1H), 6.81-6.88 (m, 2H), 15 7.20 (d, J=8.5 Hz, 1H).  
MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=633

Example 17

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene  
20      a. 6 $\alpha$ / $\beta$ -Chloro-16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene




25      A solution of thionylchloride (59 mg, 0.50 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 ml) was added to a solution of 16 $\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6 $\alpha$ -hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (316 mg, 0.368 mmol) and EtN(iPr)<sub>2</sub> (103  $\mu$ l, 0.60 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 ml). The reaction mixture was stirred for 30 min and was then partitioned between Et<sub>2</sub>O and water. The organic phase was washed with 0.1 M HCl (aq.), water, NaHCO<sub>3</sub> (aq., sat.) and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated at reduced pressure to give the crude title compound (290 mg, 90%).

$R_f$  (heptane-EtOAc, 10:1)=0.35

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.34 (m, 2H), 0.47 (m, 1H), 0.79 (m, 1H), 0.81 (s, 3H), 0.82 (s, 6H), 0.88 (d,  $J=6.8$  Hz, 6H), 2.49 (m, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 5.60 (m, 1H), 3.92 (m, 1H), 4.25 (m, 1H), 5.14 (d,  $J=8.4$  Hz, 1H (6-epimer)), 5.35-5.44 m, 2H (THP, 6-epimer)), 6.90-7.01, 7.13-7.21, 7.41 (3m, 3H).

5 b.  $16\alpha$ - (Dimethylthexyl)-silyloxy-17- (1,2-ethylene)-7 $\alpha$ -[9- (4,4,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahyd-  
10 ropyranloxy-estra-1,3,5(10)-triene



15 A solution of  $\text{LiEt}_3\text{BH}$  in THF (1.0 ml, 1.0 M) was added to a solution of  $6\alpha/\beta$ -chloro- $16\alpha$ - (dimethylthexyl)-silyloxy-17- (1,2-ethylene)-7 $\alpha$ -[9- (4,4,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (290 mg, 0.330 mmol) in DME (2.0 ml) under  $\text{N}_2$ . The temperature was raised to 85°C and the reaction mixture was stirred for 30 min. Another batch of  $\text{LiEt}_3\text{BH}$  in THF (1.0 ml, 1.0 M) was added and stirring was continued at 85°C over night. After cooling, the reaction mixture was partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure.

20

25

The residue was purified on column chromatography (heptane-EtOAc, 50:1, 20:1) to give the title compound (175 mg, 63%).


30  $R_f$  (heptane-EtOAc, 10:1)=0.39

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.34 (m, 2H), 0.47 (m, 1H), 0.78 (m, 1H), 0.80 (s, 3H), 0.83 (s, 6H), 0.88, 0.88 (2d,  $J=6.8$  Hz, 6H), 2.36 (broad t,  $J=11.3$  Hz, 1H), 2.50 (t,  $J=7.3$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 2.73, 2.74 (2d,  $J=16.9$ , 1H), 2.88 (m, 1H), 3.59 (m, 1H), 3.93 (m, 1H), 4.23 (d,  $J=7.2$  Hz, 1H), 5.37 (m, 1H), 6.76 (d,  $J=2.4$  Hz, 1H), 6.83 (m, 1H), 7.17 (d,  $J=8.5$  Hz, 1H).

35

c.  $16\alpha$ -(Dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

5




Prepared as described for Example 9-a using  $16\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (175 mg, 0.208 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 10:1, 5:1) to give the title compound (135 mg, 85%).

15  $R_f$  (heptane-EtOAc, 3:1)=0.50

$^1H$  NMR ( $CDCl_3$ )  $\delta$  0.01, 0.07 (2s, 6H), 0.34 (m, 2H), 0.48 (m, 1H), 0.79 (m, 1H), 0.81 (s, 3H), 0.83 (s, 6H), 0.88, 0.88 (2d,  $J=6.8$  Hz, 6H), 2.35 (broad t,  $J=11.4$  Hz, 1H), 2.50 (t,  $J=7.3$  Hz, 2H), 2.58 (t,  $J=7.0$  Hz, 2H), 2.71 (d,  $J=16.7$ , 1H), 2.86 (dd,  $J=16.7$ , 5.2 Hz, 1H), 4.23 (d,  $J=7.2$  Hz, 1H), 4.55 (s, 1H), 6.54 (d,  $J=2.4$  Hz, 1H), 6.60 (dd,  $J=8.5$ , 2.4 Hz 1H), 7.14 (d,  $J=8.5$  Hz, 1H).

20 d. 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene

25



Prepared as described for Example 9-b using  $16\alpha$ -(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-3-hydroxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene (85 mg, 0.112 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 5:1) to give the title compound (46 mg, 67%).


30  $R_f$  (heptane-EtOAc, 3:1)=0.27

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.47-0.59 (m, 3H), 0.72 (m, 1H), 0.82 (s, 3H), 2.09-2.24 (m, 2H), 2.28 (m, 1H), 2.37 (td, J=11.5, 3.8 Hz, 1H), 2.50 (t, J=7.4 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 2.73 (d, J=16.8, 1H), 2.87 (dd, J=16.8, 5.2 Hz, 1H), 5 4.21 (t, J=6.5 Hz, 1H), 4.61 (s, 1H), 6.54 (d, J=2.6 Hz, 1H), 6.62 (dd, J=8.4, 2.6 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H).

MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=599

Example 18

10 17-(1,2-Ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene



Prepared as described for Example 8 using 17-(1,2-ethylene)-3,16α-dihydroxy-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene (46 mg, 0.075 mmol) as starting material. The crude product was purified on column chromatography (heptane-EtOAc, 1:2) to give the title compound (36 mg, 76%).

R<sub>f</sub> (heptane-EtOAc, 1:2)=0.25

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.46-0.59 (m, 3H), 0.73 (m, 1H), 0.82 (s, 3H), 1.83-2.00 (m, 2H), 2.12-2.40 (m, 6H), 2.59-2.90 (m, 6H), 4.20 (t, J=6.6 Hz, 1H), 5.95, 6.23 (2s, 1H), 6.56 (d, J=2.4 Hz, 1H), 6.62 (m, 1H), 7.12 (d, J=8.5Hz, 1H).


MS-ESI [M-H<sub>2</sub>O+H]<sup>+</sup>=615

Example 19

30 17-(1,2-Ethylene)-3,16α-dihydroxy-6-keto-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene

a. 7α-(5-Chloro-n-pentyl)-16α-(dimethylhexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-3-

35 tetrahydropyranloxy-estra-1,3,5(10)-triene




5 Prepared as described for SM4-c using 16α-(dimethylthexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (971 mg, 8.54 mmol) and 1-chloro-5-iodo-pentane (523 mg, 2.25 mmol) as starting materials. The crude product was purified on column chromatography (heptane-EtOAc, 20:1) to give the title compound (511 mg, 44%).

$R_f$  (heptane-EtOAc, 10:1) = 0.26

<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.01, 0.07 (2s, 6H), 0.36 (m, 2H), 0.49 (m, 1H), 0.79 (m, 1H), 0.81 (s, 3H), 0.83 (s, 6H), 0.88 (d, J=6.8 Hz, 6H), 2.34 (m, 1H), 2.48 (broad d, J=11.3 Hz, 1H), 2.74 (m, 1H), 3.50 (t, J=6.7 Hz, 2H), 3.61 (m, 1H), 3.90 (m, 1H), 4.23 (d, J=7.8 Hz, 1H), 5.46 (m, 1H), 7.21 (dd, J=8.5 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 7.69 (s, 1H).

20 b. 16α-(Dimethylthexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene




25 NaI (50 mg, 0.33 mmol) and TBD-methylpolystyrene (350 mg, 0.91 mmol) were added to a solution of 7α-(5-chloro-n-pentyl)-16α-(dimethylthexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (175 mg, 0.272 mmol) and 1-methylamino-3-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-propane (175 mg, 0.660 mmol) in THF (1.0 mL) and MeCN (1.0 mL). The reaction mixture was stirred under microwave-assisted conditions at 180°C for 1 h. After cooling the reaction mixture was concentrated at reduced pressure and the

residue was purified on column chromatography (CHCl<sub>3</sub>-MeOH, 40:1, 20:1) to give the title compound (166 mg, 70%) as an oil.

$R_f$  (CHCl<sub>3</sub>-MeOH, 10:1) = 0.50


5  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.01, 0.06 (2s, 6H), 0.36 (m, 2H), 0.49  
 (m, 1H), 0.79 (m, 1H), 0.81 (s, 3H), 0.83 (s, 6H), 0.88,  
 0.89 (2d,  $J=6.8$  Hz, 6H), 2.18 (s, 3H), 2.74 (m, 1H), 3.61  
 (m, 1H), 3.90 (m, 1H), 4.24 (d,  $J=7.0$  Hz, 1H), 5.46 (m,  
 1H), 7.20 (d,  $J=8.6$  Hz, 1H), 7.30 (d,  $J=8.6$  Hz, 1H), 7.69  
 10 (s, 1H).  
 c. 17-(1,2-Ethylene)-16 $\alpha$ -hydroxy-6-keto-7 $\alpha$ -[5-[N-methyl-N-  
 3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-  
 pentyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene



Prepared as described for Example 9-b using 16 $\alpha$ -(dimethylthexyl)-silanyloxy-17-(1,2-ethylene)-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-3-tetrahydropyranloxy-estra-1,3,5(10)-triene (179 mg, 0.205 mmol) as starting material. The reaction mixture was stirred under microwave-assisted conditions at 140°C for 20 min. The crude product was purified on column chromatography (CHCl<sub>3</sub>-MeOH, 20:1) to give the title compound (94 mg, 63%) as an oil.

$R_f$  (CHCl<sub>3</sub>-MeOH, 10:1) = 0.40

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.46-0.61 (m, 3H), 0.79 (m, 1H), 0.81 (s, 3H), 2.19 (s, 3H), 2.75 (m, 1H), 3.62 (m, 1H), 3.90 (m, 1H), 4.20 (d, J=7.1 Hz, 1H), 5.47 (m, 1H), 7.21 (dm, J=8.6 Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 7.69 (m, 1H).  
d. 17-(1,2-Ethylene)-3,16α-dihydroxy-6-keto-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-  
35 propylamino]-pentyl]-estradiol-1,3,5(10)-triene



5         $MgCl_2$  (19 mg, 0.1 mmol) was added to a solution of 17-(1,2-Ethylene)-16 $\alpha$ -hydroxy-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-3-tetrahydropyranyloxy-estra-1,3,5(10)-triene (94 mg, 0.129 mmol) in MeOH (2.0 mL). The reaction mixture was  
 10      stirred under microwave-assisted conditions at 150°C for 1 h. After cooling the reaction mixture was concentrated at reduced pressure and the residue was partitioned between  $Et_2O$  and water. The organic phase was washed with water and brine, dried ( $Na_2SO_4$ ) and concentrated at  
 15      reduced pressure. The residue was purified on column chromatography ( $CHCl_3$ -MeOH, 20:1) to give the title compound (40 mg, 48%).


$R_f$  ( $CHCl_3$ -MeOH, 10:1)=0.27

20         $^1H$  NMR ( $CDCl_3$ )  $\delta$  0.46-0.63 (m, 3H), 0.80 (m, 1H), 0.80 (s, 3H), 2.14 (m, 2H), 2.42 (s, 3H), 2.53 (t,  $J=7.2$  Hz, 2H), 2.57 (t,  $J=7.0$  Hz, 2H), 4.19 (d,  $J=6.9$  Hz, 1H), 7.04 (dd,  $J=8.5$ , 2.9 Hz, 1H), 7.25 (d,  $J=8.5$  Hz, 1H), 7.41 (d,  $J=2.9$  Hz, 1H).

MS-ESI  $[M+H]^+=646$

25        Example 20

17-(1,2-Ethylene)-3,6 $\alpha$ ,16 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene



30         $NaBH_4$  (50 mg, 1.3 mmol) was added to a solution of 17-(1,2-ethylene)-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene (29 mg, 0.045 mmol) in MeOH (1.0 ml). The reaction mixture was stirred for 2 h and was then

partitioned between  $\text{Et}_2\text{O}$  and water. The organic phase was washed with water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was purified on column chromatography ( $\text{CHCl}_3\text{-MeOH}$ , 10:1, 5:1) to give the 5 title compound (20 mg, 69%).

$R_f$  ( $\text{CHCl}_3\text{-MeOH}$ , 5:1)=0.17

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.44-0.60 (m, 3H), 0.77 (m, 1H), 0.80 (s, 3H), 2.14 (m, 2H), 2.36 (s, 3H), 2.50 (t,  $J=7.1$  Hz, 2H), 2.56 (t,  $J=7.0$  Hz, 2H), 2.63 (m, 2H), 4.19 (d,  $J=6.7$  Hz, 1H), 4.89 (d,  $J=5.2$  Hz, 1H), 6.68 (dd,  $J=8.5$ , 2.4 Hz, 1H), 10 7.07 (d,  $J=8.5$  Hz, 1H), 7.20 (d,  $J=2.4$  Hz, 1H).

MS-ESI  $[\text{M}+\text{H}]^+=648$

Biological models

In vitro binding affinity to the estrogen receptor- $\alpha$  (MDS PharmaServices)

Binding affinity was determined in a displacement assay using hER- $\alpha$  (recombinant, insect Sf cells) with 0.5 nM  $^3\text{H}$ -estradiol as radioligand. The compounds were tested in concentrations from 0.03-10.0 nM. Results are given as 20  $\text{IC}_{50}$  and  $\text{Ki}$ .

In vivo estrogenic agonism (MDS PharmaServices)

Compounds were administered s.c. (10 mg/kg) for three consecutive days to a group of 5 ICR derived immature female mice weighing approx. 13 g. The animals 25 were sacrificed 24 h after the final dose and wet weight of the uterus was measured. A 50% or greater increase in the uterine weight relative to the vehicle control group indicates possible estrogen agonist activity.

In vivo estrogenic antagonism (MDS PharmaServices)

Compounds were administered s.c. (10 mg/kg) for three consecutive days to a group of 5 ICR derived immature female mice weighing approx. 13 g and challenged with estradiol-benzoate (3  $\mu\text{g}/\text{kg}$  s.c.) immediately after each daily dosing. The animals were sacrificed 24 h after 35 the final dose and wet weight of the uterus was measured. A 50% or greater reduction in the estradiol-induced

increase in uterine weight indicates possible estrogen antagonist activity.

Table 1 Biological effects of representative examples of the compounds according to the present invention

5

	ER $\alpha$ -aff (nM) Ki	IC <sub>50</sub>	In vivo agonism (%)	in vivo antagonism
ICI 164,384 SM4*	0.76	2.67	43	66
ICI 182,780*	0.41	1.43	4	66
Ex 1	1.00	3.50	1	61
Ex 4	0.71	2.48	4	58
Ex 5	0.34	1.19	8	55
Ex 8	2.91	10.2		
Ex 10	1.36	4.75		
Ex 12	0.45	1.59		
Ex 14	>10	>10		
Ex 16	0.30	1.04		
Ex 18	0.26	0.92		

\* Reference substances.

References

1. Jordan, V. C. J. Med. Chem., Vol. 46, 1081-1111 and 883-908, 2003. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicins. 1. Receptor Interactions. and 2. Clinical Considerations and New Agents.
2. Bowler, J. et al. Steroids, Vol. 54, 71-99, 1989.
- 15 3. Brzozowski, A. M. et al. Nature, Vol. 389, 753-8, 1997. Molecular basis of agonism and antagonism in the oestrogen receptor.
4. Pike, A. C. W. et al. Structure, Vol. 9, 145-53, 2001. Structural Insights into the Mode of Action of a Pure Antiestrogen.


5. Tedesco, R. et al. Bioorganic & Biomedicinal Chemistry Letters, Vol. 7, 2919-2924, 1997.  $7\alpha,11\beta$ -Disubstituted Estrogens: Probes for the Shape of the Ligand Binding Pocket in the Estrogen Receptor. See also 5 refs therein.

6. Tedesco, R. et al. Tetrahedron Letters, Vol. 38, 7997-8000, 1997. An expeditious route to  $7\alpha$ -substituted estradiol derivatives.

## CLAIMS

1. A compound of the general formula I

5



10

二

wherein

15 A is a 8-22 atoms long substituent, which convey anti-estrogenic properties to the compound and which substituent A is defined by D<sub>1-6</sub>, wherein D is chosen from the group comprising R<sub>4</sub>-C(O)R<sub>4</sub>, R<sub>4</sub>S(O)<sub>0-2</sub>R<sub>4</sub>, N(R<sub>4</sub>)<sub>3</sub>, R<sub>4</sub>OR<sub>4</sub> and R<sub>4</sub>(C<sub>6</sub>H<sub>4</sub>)R<sub>4</sub>

wherein R4 independently represents a bond, or H, or a halogenated or non-halogenated, saturated or unsaturated, mono-, di-, or trivalent C1-C12 hydrocarbon

B', B'' are H, H or H, O-R3 or O-R3, H or H, F or together represent =O;

R1 is H, or a potentially metabolically unstable group chosen from the group comprising a straight, branched, or cyclic C1-C6 alkyl, C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl;


R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl;

30 R3 is H, or C1-C3 alkyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl; and


X is methylene or a single bond, or

35 pharmaceutically acceptable salts of the compounds  
of the general formula I.


2. A compound according to claim 1,  
wherein A is



or




or




wherein Y is chosen from H or F


or



or



or




15 R<sub>1</sub> is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl;

R<sub>2</sub> is hydrogen; and


20 R<sub>3</sub> is H, or methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.

3. A compound according to claim 1 or 2,


wherein A is



or




or



wherein Y is chosen from H or F

or




B', B'' are H, H or H, O-R<sub>3</sub> or O-R<sub>3</sub>, H or H, F;

R<sub>1</sub> is H, or methyl, or acetyl, or sulphamoyl; and


R<sub>3</sub> is H, or methyl, or acyl;

4. A compound according to any one of claims 1-3,


35 wherein A is



or




or




5 and

R3 is H.


5. A compound according to any one of claims 1-4 chosen from the group comprising  
 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-  
 7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,



15 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-  
 7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,




20 11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-  
 7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-  
 butyl-methyl-amide,




30

3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-  
 fluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,


35




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,




15 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,



25 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-benzoate,




30 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




35


3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,




7 $\alpha$ -[9-[(2,2,3,3,4,4,4-Heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,



3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




35


3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,




15 3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,



3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




3,16 $\alpha$ -Dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

5



10


11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,



15


11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

20



11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,


25



30


10-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

35




11-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,

5



10


2-[9-(3,16 $\alpha$ -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,



15


11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,

20



3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,


25



30


3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

35




3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

5





3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,


20




25




30




35




11-(3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,




10- (3,6 $\alpha$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-  
triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-  
10 decanoic acid,




11-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methylamide,



6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,




6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene.





35


6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-  
10 pentyl]-estra-1,3,5(10)-triene,




11- (6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluorooctyl)-undecanoic acid,




30 10-(6 $\beta$ -Fluoro-3,16 $\alpha$ -dihydroxy-17-methylene-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-  
n-hexyl)-decanoic acid.




3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,



11-(3,6 $\beta$ ,16 $\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,




11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,




11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,

5



10


11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,



15


17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

20



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,


25




30

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,


35




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-7 $\alpha$ -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene.

25




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-  
estra-1,3,5(10)-triene.


35




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-10-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-  
(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-  
estr-1,3,5(10)-triene 3-O-benzoate,



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-acetate,




30 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-  
(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-  
estra-1,3,5(10)-triene 3-O-sulfamate,




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

5




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




15 17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

20




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

25




30 11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

35




11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

5




11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,




15 10-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

20



11-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,


25




30

2-[9-(17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,


35




11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-amide,




11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,




15 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,



20 17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,




17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

5



10



17-(1,2-Ethylene)-7 $\alpha$ -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl) sulfinyl]nonyl]-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene,




15

17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

20




25



30


17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

35




17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

5



10


11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,



15


11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

20



10-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,


25



30


11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid methylester,

35




100


11-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,




2-[9-(17-(1,2-Ethylene)-3,6 $\alpha$ ,6 $\alpha$ -trihydroxy-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-  
10 nonafluoro-n-hexyl)-malonic acid,




11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-  
1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid n-butyl-methyl-  
amide,



11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,




17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-  
1,3,5(10)-triene,




101


17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
 [(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-  
 1,3,5(10)-triene,




17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
 [(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-  
 10 1,3,5(10)-triene 3-O-sulfamate,




15 17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[9-  
 [(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-  
 1,3,5(10)-triene,



17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-  
 methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propyl-  
 amino]-pentyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-  
 30 methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propyl-  
 amino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,



102


17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

5



17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,


10



15


11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

20



11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,


25



30


11-(17-(1,2-Ethylene)-6 $\beta$ -fluoro-3,16 $\alpha$ -dihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

35




103


17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,




17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,



17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,



11-(17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,




35

104


11-(17-(1,2-Ethylene)-3,6 $\beta$ ,6 $\alpha$ -trihydroxy-estra-1,3,5(10)-triene-7 $\alpha$ -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

5



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,


15




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

25


20



17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6-keto-7 $\alpha$ -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,




30




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

35




17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\alpha$ -methoxy-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

5



10

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,




, and

15

17-(1,2-Ethylene)-3,16 $\alpha$ -dihydroxy-6 $\beta$ -methoxy-7 $\alpha$ -[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene

20



6. A compound according to any one of claims 1-5 for use as a medicament.

7. Use of a compound according to any one of claims 1-5 for the manufacturing of a medicament for the treatment of an estrogen related disorder or condition that benefits from antiestrogen treatment.

8. Use according to claim 7, wherein the estrogen related disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.

9. Use according to claim 7 or 8, wherein the estrogen related disorder is estrogen dependent breast cancer.

10. A pharmaceutical composition comprising a compound according to any one of claims 1-5, admixed with 5 one or more pharmaceutically acceptable excipients or carriers.

11. A pharmaceutical composition according to claim 10, wherein the excipients are chosen from the group comprising filling agents, lubricants, flavours, colourings, 10 sweetenings, buffers, acidifying agents, diluents and preservatives.

12. A pharmaceutical composition according to any one of claims 10-11, which is administered orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, or vaginally; preferably orally, transdermally or intranasally.

13. A method of treatment comprising administration of a pharmaceutically effective amount of compound according to claim 1-5 or a pharmaceutical composition according to claim 10-12 to a subject suffering from an estrogen dependent disorder or condition.

14. A method of treatment according to claim 13, wherein the estrogen dependent disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.

15. A method of treatment according to claim 13 or 14, wherein the estrogen dependent disorder is estrogen dependent breast cancer.

## ABSTRACT

The present invention relates to novel compounds which are 7 $\alpha$ -substituted 17-alkylene-16 $\alpha$ -hydroxy steroid estrogens. This invention specifically relates to estrogen derivatives where the 7 $\alpha$ -substituent is chosen in such a way that it conveys anti-estrogenic properties to the compound. The present invention also relates to use of said compounds as a medicament, and for the treatment of estrogen dependent disorders, a pharmaceutical composition comprising one or more of said compounds and a method of treatment.